

STIC-Biotech/ChemLib

From: Steadman, David (AU1652)
Sent: Wednesday, May 30, 2001 8:03 AM
To: STIC-Biotech/ChemLib
Subject: 09/526,193 SEQ SEARCH

NAME: David Steadman
AU: 1652
Date: 05/30/01
Room: 10D-04
Mailbox #: 10C-01 M3
Serial #: 09/526,193

Please search the following sequence(s) in commercial databases:

Amino Acid

Amino acids 1-60 of SEQ ID NO:1 against amino acid databases
Amino acids 1-60 of SEQ ID NO:1 against nucleic acid databases

Thank you,
David Steadman

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 13:04:34 ; Search time 49.05 Seconds
(without alignments)
143.374 Million cell updates/sec

Title: us-09-526-193a-1_copy_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKLNLTFRRL.....SVRLSYPPYEQHECHFPNKA 60

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 374700 seqs, 117207915 residues

Total number of hits satisfying chosen parameters: 374700

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_15.*

1: sp_archaea.*

2: sp_bacteria.*

3: sp_fungi.*

4: sp_human.*

5: sp_invertebrate.*

6: sp_mammal.*

7: sp_mhc.*

8: sp_organelle.*

9: sp_phase.*

10: sp_plant.*

11: sp_rodent.*

12: sp_unclassified.*

13: sp_vertebrate.*

14: sp_virus.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	334	100.0	70	4 Q9NS76	Q9ns76 homo sapien
2	334	100.0	100	4 Q9NP93	Q9np93 homo sapien
3	334	100.0	2261	4 Q9NQV4	Q9nqv4 homo sapien
4	230	68.9	2146	4 Q9NR73	Q9nr73 homo sapien
5	185	55.4	2310	11 Q35600	O35600 mus musculus
6	179	53.6	2281	6 Q02698	O02698 bos taurus
7	100	29.9	602	5 Q9N403	Q9n403 caenorhabdi
8	78	23.4	1713	5 Q9VRG4	Q9vrg4 drosophila
9	71.5	21.4	707	10 Q9T050	Q9t050 arabidopsis
10	65.5	19.6	307	13 Q9PVW2	Q9pvw2 oryzias lat
11	65.5	19.6	307	13 Q9PVW1	Q9pvw1 oryzias lat
12	61.5	18.4	129	10 Q9ZPB9	Q9zpb9 crawfurdia
13	61.5	18.4	2272	5 Q9VZS7	Q9vzs7 drosophila
14	61	18.3	218	5 Q9NF52	Q9nf52 drosophila
15	60.5	18.1	598	10 Q82747	Q82747 arabidopsis
16	60	18.0	1802	5 Q9TXV8	Q9txv8 caenorhabdi
17	60	18.0	1880	13 Q9IBF1	Q9ibf1 takifugu pa
18	59.5	17.8	383	10 Q82729	Q82729 borago offi
19	59.5	17.8	473	5 Q94789	Q94789 trichosteon

20	59.5	17.8	512	5 P92039	P92039 haemochus
21	58.5	17.5	426	5 Q96760	Q96760 ascaris suu
22	58.5	17.5	586	10 Q9SNT3	Q9snt3 oryza sativ
23	58	17.4	250	2 Q9RSP1	Q9rsp1 delinococcus
24	57	17.1	1717	13 Q90519	Q90519 fugu rubrip
25	56.5	16.9	272	4 Q9URB8	Q9urb8 homo sapien
26	56.5	16.9	383	10 Q9LLL7	Q9lll7 sesamum ind
27	56.5	16.9	870	4 Q60309	Q60309 homo sapien
28	56.5	16.9	1400	5 Q20766	Q20766 caenorhabdi
29	56.5	16.9	1977	4 Q15858	Q15858 homo sapien
30	56.5	16.9	3268	3 Q03280	Q03280 saccharomyc
31	56	16.8	373	4 Q9NS66	Q9ns66 homo sapien
32	56	16.8	373	11 Q9UJH2	Q9ujh2 rattus norv
33	56	16.8	403	10 Q9LPG9	Q9lpg9 arabidopsis
34	56	16.8	512	2 Q9JVA8	Q9jva8 neisseria m
35	56	16.8	524	2 Q9K0A2	Q9k0a2 neisseria m
36	56	16.8	830	10 Q65482	Q65482 arabidopsis
37	56	16.8	1215	2 Q92771	Q92771 chlamydia p
38	56	16.8	1215	2 Q9JS99	Q9js99 chlamydia p
39	55.5	16.6	372	5 Q18933	Q18933 caenorhabdi
40	55.5	16.6	378	10 Q24499	Q24499 hellanthus
41	55.5	16.6	495	2 Q53300	Q53300 mycobacteri
42	55.5	16.6	706	5 Q9XUG5	Q9xug5 caenorhabdi
43	55.5	16.6	837	4 Q75173	Q75173 homo sapien
44	55.5	16.6	837	4 Q9UN83	Q9un83 homo sapien
45	55	16.5	276	11 Q60828	Q60828 mus musculu

ALIGNMENTS

RESULT	1	PRELIMINARY;	PRT;	70 AA.
Q9NS76	AC	Q9NS76;		
DT	01-OCT-2000 (Tremblrel. 15, Created)			
DT	01-OCT-2000 (Tremblrel. 15, Last sequence update)			
DT	01-OCT-2000 (Tremblrel. 15, Last annotation update)			
DE	ABC1 (FRAGMENT).			
GN	ABC1.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RC	SEQUENCE FROM N.A.			
RC	TISSUE=PLACENTA;			
RA	Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T.,			
RA	Shioda S., Ueda K., Inagaki N.;			
RT	"Cloning, characterization, and tissue distribution of the ABC			
RT	transporter ABC2.";			
RL	Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.			
DR	EMBL; AB037924; BAB07875.1; -			
FT	NON_TER			
SQ	SEQUENCE 70 AA; 8383 MW; C6DBDEFE854F034F CRC64;			

Query Match 100.0%; Score 334; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 1.1e-34;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MACWPQLRLLLKLNLTFRRLTQCOLLEVAWPLFILLISVRLSYPPYEQHECHFPNKA 60	
DB	1	MACWPQLRLLLKLNLTFRRLTQCOLLEVAWPLFILLISVRLSYPPYEQHECHFPNKA 60	

RESULT	2	PRELIMINARY;	PRT;	100 AA.
Q9NP93	ID	Q9NP93		
AC	Q9NP93;			
DT	01-OCT-2000 (Tremblrel. 15, Created)			
DT	01-OCT-2000 (Tremblrel. 15, Last sequence update)			
DT	01-OCT-2000 (Tremblrel. 15, Last annotation update)			

DE ATP BINDING CASSETTE TRANSPORTER 1 (FRAGMENT).

GN ABCA1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=PLACENTA;
RA Pullinger C.R., Hakamata H., Duchateau P.N., Eng C., Aouizerat B.E.,
RA Fielding C.J., Kane J.P.;
RT "Analysis of hABC1 gene 5' end: additional peptide sequence, promoter
region, and four polymorphisms";
RL Biochem. Biophys. Res. Commun. 271:0-0(2000).
DR EMBL: AF258626; AAF69516.1; -;
DR EMBL: AF258624; AAF69516.1; JOINED.
DR EMBL: AF258625; AAF69516.1; JOINED.
DR EMBL: AF258627; AAF69513.1; -;
FT NON-TER 100 100
SQ SEQUENCE 100 AA; 11530 MW; ABEBA02D542CE853 CRC64;

Query Match 100.0%; Score 334; DB 4; Length 100;

Best Local Similarity 100.0%; Pred. No. 1.5e-34;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

DB 1 MACWPQLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

RESULT 3

ID Q9NOV4 PRELIMINARY; PRT; 2261 AA.

AC Q9NOV4;

DT 01-OCT-2000 (TReMBLrel. 15, Created)

DT 01-OCT-2000 (TReMBLrel. 15, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE ABCA1.

GN ABCA1.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Santamarina-Pojo S., Peterson K.M., Knapper C.L., Qiu Y.,

RA Freeman L.A., Cheng J.-F., Osorio J., Remaley A.T., Yang X.-P.,

RA Haudenschild C.C., Prades C., Chimini G., Blackmon E.E.,

RA Francois T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P.,

RA Fredrickson D.S., Brewer H.B. Jr.;

RT "Complete genomic sequence of the human ABCA1 gene: Analysis of the

human and mouse ATP-binding cassette A promoter";

Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).

DR EMBL: AF275948; AAF86276.1; -;

SQ SEQUENCE 2261 AA; 254324 MW; BA27D9B217ACAA33 CRC64;

Query Match

Best Local Similarity 100.0%; Score 334; DB 4; Length 2261;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

DB 1 MACWPQLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

RESULT 4

ID Q9NR73

AC Q9NR73 PRELIMINARY; PRT; 2146 AA.

DT 01-OCT-2000 (TReMBLrel. 15, Created)

DT 01-OCT-2000 (TReMBLrel. 15, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE MACROPHAGE ABC TRANSPORTER.

GN ABCA7.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Kaminski W.E., Orso E., Diederich W., Klucken J., Drobnik W.,

RA Schmitz G.;

RT "Identification of a Novel Human Sterol-Sensitive ATP-Binding Cassette

Transporter (ABCA7)";

RL Biochem. Biophys. Res. Commun. 273:532-538(2000).

DR EMBL: AF250238; AAF85794.1; -;

SQ SEQUENCE 2146 AA; 234468 MW; 679B16EB2D75FF0D CRC64;

Query Match 68.9%; Score 230; DB 4; Length 2146;

Best Local Similarity 67.8%; Pred. No. 2.3e-20;

Matches 40; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 59

DB 1 MAFWTQLMLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 59

RESULT 5

Q35600

ID Q35600 PRELIMINARY; PRT; 2310 AA.

AC Q35600;

DT 01-JAN-1998 (TReMBLrel. 05, Created)

DT 01-JAN-1998 (TReMBLrel. 05, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE ATP-BINDING CASSETTE TRANSPORTER.

GN ABCA4 OR ABC10 OR ABCR.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6;

RX MEDLINE=97345663; PubMed=9202155;

RA Azarian S.M., Travis G.H.;

RT "The photoreceptor rim protein is an ABC transporter encoded by the

gene for recessive Stargardt's disease (ABCR).";

FEBS Lett. 409:247-252(1997).

DR EMBL: AF000149; AAC23916.1; -;

DR MGD: MGI:109424; Abca4.

DR INTERPRO: IPR001617; -;

DR PFAM: PF00005; ABC_tran; 2

DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.

KW ATP-binding.

SQ SEQUENCE 2310 AA; 260207 MW; 8370C6C8A62EF294 CRC64;

Query Match

Best Local Similarity 55.4%; Score 185; DB 11; Length 2310;

Matches 32; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

OY 6 QLRLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

DB 6 QIQLLLKKNLTFRRRTQCLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60

RESULT 6

O02698

ID O02698 PRELIMINARY; PRT; 2281 AA.

AC O02698;

DT 01-JUL-1997 (TReMBLrel. 04, Created)

DT 01-JUL-1997 (TReMBLrel. 04, Last sequence update)

DT 01-JUN-2000 (TReMBLrel. 14, Last annotation update)

DT	01-MAY-2000 (TREMBLrel. 13, Last sequence update)
DT	01-JUN-2000 (TREMBLrel. 14, Last annotation update)
DE	CGI718 PROTEIN.
GN	Drosophila melanogaster (Fruit fly).
OS	Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC	Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC	Ephydroidea; Drosophilidae; Drosophila.
OX	NCBI_TaxID=7227;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	STRAIN=BERKELEY;
RC	MEDLINE=Z0196006; PubMed=107311132;
RA	Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA	Ananides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA	Gordon R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA	Sutton G.G., Wortman J.R., Vandell M.D., Zhang Q., Chen L.X.,
RA	Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe W., Pfeiffer B.D.,
RA	Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA	Abdil J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA	Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA	Beeson K.Y., Benos P.V., Berland B.P., Bhandari D., Bolshakov S.,
RA	Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotlier P.,
RA	Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA	Cherry J.M., Cawley S., Dahlke C., Davidson L.B., Davies P.,
RA	de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA	Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA	Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA	Fosler C., Gabrieli A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA	Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA	Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA	Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwan C.,
RA	Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA	Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA	Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA	Liu X., Mattel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA	Markulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA	Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA	Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA	Palazzo K., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA	Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA	Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA	Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA	Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA	Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissbach J.,
RA	Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA	Ye J., Yeh R.-F., Zaverl J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA	Zheng X.-H., Zhong F.N., Zhong W., Zhou X., Zhu S.,
RA	Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.:
RT	"The genome sequence of Drosophila melanogaster."
RL	Science 287:2185-2195(2000).
DR	ENBL: AE003568; AAF50837.1; -
DR	FLYBASE: FBgn0031170; CGI718.
DR	INTERPRO: IPR001617; -
DR	PFAM: PF00005; ABC_tran; 2.
DR	PROSITE: PS00211; ABC_TRANSPORTER; 1.
SQ	SEQUENCE 1713 AA; 192888 MW; 9DE20D3BF9DCICA CRC64;

Query Match	23.4%;	Score 78;	DB 5;	Length 1713;
Best Local Similarity	37.5%;	Pred. NO. 0.19;		
Matches 15;	Conservative	8;	Mismatches 17;	Indels 0; Gaps

QY	4	WPQLRLLLNKLTFRRCQTCCOLLELVANPLFIELILISVR	43
		:	:
	+		+
Db	7	WDRFVLLMKNTLWNHKWKQMVIELVLPALFSLLLVLVR	46

RESULT	9
Q9T050	
ID	Q9T050 PRELIMINARY; prt: 707 AA.
AC	Q9T050;
DT	01-MAY-2000 (TREMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
 DE HYPOTHETICAL 79.4 KDA PROTEIN.
 GN T26X18.20 OR AT4G1810.
 OS Arabidopsis thaliana (Mouse-ear cress).
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
 OC Brassicales; Brassicaceae; Arabidopsids.
 OX NCBI_TaxID=3702;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bevan M., Hilbert H., Braun M., Holzer E., Brandt A., Duesterhoeft A.,
 RA Bancroft I., Mewes H.W., Mayer K.F.X., Lemcke K., Mannhaupt G.,
 RA Schueller C.;
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RA EU Arabidopsis sequencing project;
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RA Hilbert H., Braun M., Holzer E., Brandt A., Duesterhoeft A.,
 RA Mewes H.W., Lemcke K., Mayer K.F.X.;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RP SEQUENCE FROM N.A.
 RA EU Arabidopsis sequencing project;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AL078606; CAB4319.1; -;
 DR EMBL; AL161532; CAB78224.1; -;
 KW Hypothetical protein.
 SQ SEQUENCE 707 AA; 79418 MW; DALF8F4BF88A7FF2 CRC64;

 Query Match 21.4%; Score 71.5; DB 10; Length 707;
 Best Local Similarity 36.7%; Pred. No. 0.56; 24; Indels 7; Gaps 2;
 Matches 22; Conservative 7; Mismatches 24; Indels 7; Gaps 2;

 QY 1 MACWPQLRLLLW-----KNLTFRRRTQCQLLEAVAPLFIPLILSVRLSPYPPYEQHECH 55
 DB 390 MACGPALAGLQDFDKIKNTFTFNQDTLPGWMAVALLYLVLWLAISFR--EPAREPEIH 447

 RESULT 10
 Q9PVM2 PRELIMINARY; PRT; 307 AA.
 ID Q9PVM2
 AC Q9PVM2
 DT 01-MAY-2000 (TrEMBLrel. 13, Created).
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE OLFACTORY RECEPTOR 1.
 GN MF0R1.
 OS Oryzias latipes (Medaka fish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziinae; Oryzias.
 OX NCBI_TaxID=8090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Sun H., Kondo R., Shima A., Naruse K., Hori H., Chigusa S.I.;
 RC STRAIN-NGY;
 RT "Evolutionary analysis of putative olfactory receptor genes of medaka
 fish, Oryzias latipes.";
 RL Gene 231:137-145(1999).
 DR EMBL; AB022646; BAA84275.1; -;
 DR INTERPRO: IPR000276; -;
 DR PFAM: PF00001; 7tm_1; 1.
 DR PRINTS: PR00237; GPCRHOPOPSN.
 DR PROSITE: PS00237; G_PROTEIN_RECEPTOR; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 307 AA; 35400 MW; E14065B68FCCBEF8 CRC64;

 Query Match 19.6%; Score 65.5; DB 13; Length 307;
 Best Local Similarity 33.3%; Pred. No. 1.5;
 Matches 18; Conservative 8; Mismatches 21; Indels 7; Gaps 2;

 QY 3 CWPQLRLLLKNLFRRTQCQLLEAVAPLFIPLILSVRLSPYPPYEQHECHF 56
 DB 125 CKP-----LQYOSLSMKRRVTWMLLSLWLPFLQLTVAISGKVI---INORPCSF 171

 RESULT 12
 Q9ZPB9 PRELIMINARY; PRT; 129 AA.
 ID Q9ZPB9
 AC Q9ZPB9
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
 DE MATURASE (FRAGMENT).
 GN YCF14 OR MATK.
 OS Crawfordia speciosa.
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
 OC Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I;
 OC Gentianales; Gentianaceae; Crawfordia.
 OX NCBI_TaxID=82711;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Thiv M., Kadereit J.W.;
 RC "The phylogenetic relationships and evolution of the Canarian laurel
 forest endemic Ixanthus viscosus (Ait.) Griseb. (Gentianaceae):
 evidence from matk and ITS sequences.";
 RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ010512; CAB37008.1; -;
 DR MENDEL; 40044; Crasp; ycf14; 40044.

Query Match 19.6%; Score 65.5; DB 13; Length 307;
 Best Local Similarity 33.3%; Pred. No. 1.5;
 Matches 18; Conservative 8; Mismatches 21; Indels 7; Gaps 2;

 QY 3 CWPQLRLLLKNLFRRTQCQLLEAVAPLFIPLILSVRLSPYPPYEQHECHF 56
 DB 125 CKP-----LQYOSLSMKRRVTWMLLSLWLPFLQLTVAISGKVI---INORPCSF 171

 RESULT 11
 Q9PVM1 PRELIMINARY; PRT; 307 AA.
 ID Q9PVM1
 AC Q9PVM1
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE OLFACTORY RECEPTOR 2.
 GN MF0R2.
 OS Oryzias latipes (Medaka fish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziinae; Oryzias.
 OX NCBI_TaxID=8090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Sun H., Kondo R., Shima A., Naruse K., Hori H., Chigusa S.I.;
 RC STRAIN-NGY;
 RT "Evolutionary analysis of putative olfactory receptor genes of medaka
 fish, Oryzias latipes.";
 RL Gene 231:137-145(1999).
 DR EMBL; AB022647; BAA84276.1; -;
 DR INTERPRO: IPR000276; -;
 DR PFAM: PF00001; 7tm_1; 1.
 DR PRINTS: PR00237; GPCRHOPOPSN.
 DR PROSITE: PS00237; G_PROTEIN_RECEPTOR; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 307 AA; 35678 MW; BCA9C5FDF050B7D8 CRC64;

 Query Match 19.6%; Score 65.5; DB 13; Length 307;
 Best Local Similarity 33.3%; Pred. No. 1.5;
 Matches 18; Conservative 8; Mismatches 21; Indels 7; Gaps 2;

 QY 3 CWPQLRLLLKNLFRRTQCQLLEAVAPLFIPLILSVRLSPYPPYEQHECHF 56
 DB 125 CKP-----LQYOSLSMKRRVTWMLLSLWLPFLQLTVAISGKVI---INORPCSF 171

 RESULT 12
 Q9ZPB9 PRELIMINARY; PRT; 129 AA.
 ID Q9ZPB9
 AC Q9ZPB9
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
 DE MATURASE (FRAGMENT).
 GN YCF14 OR MATK.
 OS Crawfordia speciosa.
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
 OC Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I;
 OC Gentianales; Gentianaceae; Crawfordia.
 OX NCBI_TaxID=82711;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Thiv M., Kadereit J.W.;
 RC "The phylogenetic relationships and evolution of the Canarian laurel
 forest endemic Ixanthus viscosus (Ait.) Griseb. (Gentianaceae):
 evidence from matk and ITS sequences.";
 RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ010512; CAB37008.1; -;
 DR MENDEL; 40044; Crasp; ycf14; 40044.

```

RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
DR EMBL: AE003477; AAF47740.1; -.
DR FLYBASE: FBgn0035420; CG14967.
SQ SEQUENCE 2272 AA; 259619 MW; 4102D7EC483A3298 CRC64;

Query Match 18.4%; Score 61.5; DB 5; Length 2272;
Best Local Similarity 27.5%; Pred. No. 28;
Matches 22; Conservative 9; Mismatches 26; Indels 23; Gaps

QY 2 ACWPQLRLLWKNLTFRRRTQCQL-----LEVAMP-----LFIFLI 38
Db 1142 ACWEPLRLLHGRUTLIAQKFTILLHASLDPYNTEEMELTNWNCGIVLTNAKIMFGEL 120
QY 39 LISVRLSPYPYEQHECHFPN 58
Db 1202 NVTVRTASRYDDCRLHFPN 1221

RESULT 14
Q9NF52 PRELIMINARY; PRT; 218 AA.
AC AC Q9NF52;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DE BACN519.GS.1.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA Murphy L., Harris D., Barrell B.;
RT "Sequencing the distal X chromosome of Drosophila melanogaster.";
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Benos P.;
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; ALI21800; CAB58006.1; -.
SQ SEQUENCE 218 AA; 25502 MW; E9DF6B80F0356CBA CRC64;

Query Match 18.3%; Score 61; DB 5; Length 218;
Best Local Similarity 23.3%; Pred. No. 4;
Matches 14; Conservative 17; Mismatches 27; Indels 2; Gaps

QY 1 MACWPQLRLLWKNLTFRRRTQCQL-LLEVAMPFLIF-LILISVRLSPYPYEQHECHFPN 58
Db 90 LAMWRQRHFYVVKWMTLRKARLLSLAILIAWMLIYGIIVTDLPLRHVAMDSGDQHRPN 149

RESULT 15
Q82747 PRELIMINARY; PRT; 598 AA.
AC AC Q82747;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DE HYPOTHETICAL 67.7 KDA PROTEIN.
GS F7H19.170 OR AT4G22990.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
OC Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Peters S.A., van Staveren M., Dirkse W., Stiekema W., Bancroft I.

```

```

RA      Mewes H.W., Mayer K.F.X., Schueller C., Bevan M.;
RRL    Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN      [2]
RP      SEQUENCE FROM N.A.
RR      Peters S.A., van Staveren M., Dirkse W., Stiekema W., Mewes H.W.,
RRL    Lemcke K., Mayer K.F.X.;
RNA     Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN      [3]
RP      SEQUENCE FROM N.A.
RR      EU Arabidopsis sequencing project;
RRL    Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RNA     EMBL; AL031018; CAA19814.1; -
RDL    EMBL; AL161558; CAB79254.1; -
RK      Hypothetical protein
KW
SQ      SEQUENCE   598 AA;  67750 MW;  89F8821BC5081826 CRC64;
        Query Match          18.1%; Score 60.5; DB 10; Length 598;
        Best Local Similarity 30.5%; Pred. No. 11;
        Matches 18; Conservative 11; Mismatches 21; Indels 9; Gaps
                                3;
Oy      1 MACWP-----QURLLNKLTFRRTQTCLLEVAWPLFIILLTVRSUYPPEQHE 53
       ||| | :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|
Dd      387 MACGPALAGLLQIRFYIK--LTNQDTLPQWNMAVAM--LIYLVLAISPREAREPDEE 442

```

Search completed: May 31, 2001, 13:09:59
Job time: 325 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 13:03:59 ; Search time 31.1 Seconds
(without alignments)
66.088 Million cell updates/sec.

Title: US-09-526-193A-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLKLNKLTFR...SVRLSYPPYRQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 93435 seqs, 34255486 residues

Total number of hits satisfying chosen parameters: 93435

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_39:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	334	100.0	2261	1 ABC1_HUMAN	O95477 homo sapien
2	334	100.0	2261	1 ABC1_MOUSE	P41233 mus musculus
3	180	53.9	2273	1 ABCR_HUMAN	P78363 homo sapien
4	84	25.1	1704	1 ABC3_HUMAN	O99758 homo sapien
5	65.5	19.6	778	1 FTSK_COXBU	P39920 coxiella bu
6	60.5	18.1	511	1 ACH5_CAEEL	Q23022 caenorhabdi
7	58.5	17.5	383	1 F062_SOYBN	P48631 glycine max
8	57	17.1	1093	1 SYV_NEUCR	P28350 neurospora
9	57	17.1	1103	1 CYGF_BOVIN	O02740 bos taurus
10	56.5	16.9	870	1 Y563_HUMAN	O60309 homo sapien
11	56	16.8	463	1 DSDR_FUGRU	P53454 fugu rubrip
12	56	16.8	921	1 CR2A_BOVIN	P14099 bos taurus
13	56	16.8	941	1 CR2A_HUMAN	O00408 homo sapien
14	55.5	16.6	436	1 ACHX_ONCVO	P54247 onchocerca
15	55.5	16.6	837	1 AT54_HUMAN	O75173 homo sapien
16	55	16.5	357	1 YCF4_ECOLI	P75955 escherichia
17	55	16.5	383	1 F06E_ARATH	P46313 arabidopsis
18	55	16.5	928	1 CR2A_RAT	Q01062 rattus norv
19	54	16.2	2005	1 CIN2_HUMAN	O99250 homo sapien
20	54	16.2	2005	1 CIN2_RAT	P04775 rattus norv
21	53.5	16.0	333	1 CXCL_HUMAN	P46094 homo sapien
22	53.5	16.0	1682	1 CIN6_HUMAN	Q01118 homo sapien
23	53	15.9	475	1 DMR_MENPI	Q98500 mentha pipe
24	53	15.9	638	1 NTGL_BOVIN	P02935 bos taurus
25	53	15.9	1229	1 Q43_TRYBB	Q99280 trypanosoma
26	52.5	15.7	282	1 NU2M_CAEEL	P24889 caenorhabdi
27	52.5	15.7	345	1 CSAR_CAVPO	O70129 cavia porce
28	52.5	15.7	434	1 FSR_ERWCH	O53900 erwinnia chr
29	52.5	15.7	465	1 DDDR_XENLA	P42291 xenopus lae
30	52.5	15.7	676	1 EXL1_HUMAN	O92935 homo sapien
31	52	15.6	378	1 EXT1_CAEEL	O01704 caenorhabdi
32	52	15.6	633	1 NTGL_MOUSE	P28571 mus musculus
33	52	15.6	633	1 NTGL_RAT	P28572 rattus norv

RESULT 1

ID	ABC1_HUMAN	STANDARD:	PRT:	2261 AA.
AC	O95477: Q9UN08; Q9UN07: Q9UN06; Q9NQV4; Q9UN09;			
DT	01-OCT-2000 (Rel. 40, Created)			
DT	01-OCT-2000 (Rel. 40, Last sequence update)			
DT	01-OCT-2000 (Rel. 40, Last annotation update)			
DE	ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 1 (ATP-BINDING CASSETTE TRANSPORTER 1) (ATP-BINDING CASSETTE 1) (ABC-1) (CHOLESTEROL EFFLUX REGULATORY PROTEIN).			
DE	REGULATORY PROTEIN).			
GN	ABCAL OR ABC1 OR CERP.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RX	SEQUENCE FROM N.A.			
RX	MEDLINE=20345099; PubMed=10884428;			
RA	Santamarina-Fojo S., Peterson K.M., Knapper C.L., Qiu Y., Freeman L.A., Cheng J.-F., Osorio J., Remaley A.T., Yang X.-P., Haudenschild C.C., Prades C., Chimini G., Blackmon E.E., Francois T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P., Fredrickson D.S., Brewer H.B. Jr.;			
RT	"Complete genomic sequence of the human ABCAL gene: analysis of the human and mouse ATP-binding cassette A promoter."			
RL	Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Skin;			
RA	Schwartz K., Lawn R.M., Wade D.P.;			
RT	"ABCA1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR."			
RL	Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.			
RN	[3]			
RP	SEQUENCE OF 21-2261 FROM N.A.			
RX	PubMed=10092505;			
RA	Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W., Schmitz G.;			
RT	"Molecular cloning of the human ATP-binding cassette transporter 1 (ABCA1): evidence for dimeric regulation in macrophages."			
RL	Biochem. Biophys. Res. Commun. 257:29-33(1999).			
RN	[4]			
RP	SEQUENCE OF 21-2261 FROM N.A.			
RX	MEDLINE=99364413; PubMed=10431238;			
RA	Rust S., Rosier M., Funke H., Real J., Amoura Z., Plette J.-C., Delaunay J.-F., Brewer H.B., Duverger N., Deneffe P., Assmann G.;			
RT	"Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1."			
RL	Nat. Genet. 22:352-355(1999).			
RN	[5]			
RP	VARIANTS TD ARG-597; LEU-693 DEL AND ARG-1477.			
RX	MEDLINE=99364411; PubMed=10431236;			
RA	Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.-H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.P., Louber O., Ouellette B.F.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D.,			

P48067 homo sapien
Q9N46 homo sapien
P08104 rattus norv
Q14524 homo sapien
P15389 rattus norv
Q10045 caenorhabdi
Q9R0m1 mus musculu
Q99500 homo sapien
P46071 porphyromon
P35498 homo sapien
P04774 rattus norv
Q02458 proteus mir

ALIGNMENTS

RA Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.,
Hayden M.R.;
RT "Mutations in ABC1 in Tangier disease and familial high-density
RT lipoprotein deficiency.";
RL Nat. Genet. 22:336-345(1999).
RN [6]
RP VARIANTS TD SER-590; SER-935 AND VAL-937.
RX MEDLINE-99364412; PubMed-10431237;
RA Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A.,
RA Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M.,
RA Kaminski W.E., Hammann H.W., Oette K., Rothe G., Aslanidis C.,
RA Lackner K.J., Schmitz G.;
RT "The gene encoding ATP-binding cassette transporter 1 is mutated in
RT Tangier disease.";
RL Nat. Genet. 22:347-351(1999).
RN [7]
RP VARIANTS TD LEU-1289 AND HIS-1800.
RX MEDLINE-20171564; PubMed-10706591;
RA Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA Van Berdwegh P., Goldkamp A.L., Thurston L.M., FitzGerald M.G.,
RA Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA Ordovas J.M., Freeman M.W., Brown R.H. Jr., Gu J.Z.;
RT "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT tangier disease kindreds.";
RL J. Lipid Res. 41:433-441(2000).
CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
CC TRANSPORT.
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED, BUT MOST ABUNDANT IN
CC MACROPHAGES.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN.
CC -1- DISEASE: DEFECTS IN ABCA1 ARE A CAUSE OF TANGIER DISEASE (TD). TD
CC IS A RECESSIVE DISORDER CHARACTERIZED BY ABSENCE OF HIGH DENSITY
CC LIPOPROTEIN (HDL) CHOLESTEROL FROM PLASMA, HEPATOSPLENOMEGALY,
CC PERIPHERAL NEUROPATHY, AND FREQUENTLY PREMATURE CORONARY ARTERY
CC DISEASE (CHD).
CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS). MDR SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF275948; AAF86276.1; -;
DR EMBL; AF285167; AAF98175.1; -;
DR EMBL; AJ012376; CAA10005.1; ALT_INIT.
DR EMBL; AF165281; AAD49849.1; ALT_INIT.
DR EMBL; AF165286; AAD49851.1; -;
DR EMBL; AF165282; AAD49851.1; JOINED.
DR EMBL; AF165283; AAD49851.1; JOINED.
DR EMBL; AF165284; AAD49851.1; JOINED.
DR EMBL; AF165285; AAD49851.1; JOINED.
DR EMBL; AF165306; AAD49852.1; -;
DR EMBL; AF165287; AAD49852.1; JOINED.
DR EMBL; AF165288; AAD49852.1; JOINED.
DR EMBL; AF165289; AAD49852.1; JOINED.
DR EMBL; AF165290; AAD49852.1; JOINED.
DR EMBL; AF165291; AAD49852.1; JOINED.
DR EMBL; AF165292; AAD49852.1; JOINED.
DR EMBL; AF165293; AAD49852.1; JOINED.
DR EMBL; AF165294; AAD49852.1; JOINED.
DR EMBL; AF165295; AAD49852.1; JOINED.
DR EMBL; AF165296; AAD49852.1; JOINED.
DR EMBL; AF165297; AAD49852.1; JOINED.
DR EMBL; AF165298; AAD49852.1; JOINED.
DR EMBL; AF165299; AAD49852.1; JOINED.
DR EMBL; AF165300; AAD49852.1; JOINED.
DR EMBL; AF165301; AAD49852.1; JOINED.
DR EMBL; AF165302; AAD49852.1; JOINED.
DR EMBL; AF165303; AAD49852.1; JOINED.
DR EMBL; AF165304; AAD49852.1; JOINED.
DR EMBL; AF165305; AAD49852.1; JOINED.
DR EMBL; AF165306; AAD49852.1; JOINED.
DR EMBL; AF165307; AAD49854.1; -;
DR EMBL; AF165307; AAD49854.1; JOINED.
DR EMBL; AF165308; AAD49854.1; JOINED.
DR EMBL; AF165310; AAD49853.1; -;
DR MIM; 600046; -;
DR MIM; 205400; -;
DR InterPro; IPR001617; -;
DR Pfam; PF00005; ABC_tran; 2.
DR PROSITE; PS0211; ABC_TRANSPORTER; 1.
KW ATP-binding; Glycoprotein; Transmembrane; Transport;
KW Disease mutation.
FT TRANSMEM 26 42 POTENTIAL.
FT TRANSMEM 640 656 POTENTIAL.
FT TRANSMEM 690 706 POTENTIAL.
FT TRANSMEM 717 733 POTENTIAL.
FT TRANSMEM 749 765 POTENTIAL.
FT TRANSMEM 771 787 POTENTIAL.
FT TRANSMEM 1041 1057 POTENTIAL.
FT TRANSMEM 1351 1367 POTENTIAL.
FT TRANSMEM 1661 1677 POTENTIAL.
FT TRANSMEM 1708 1724 POTENTIAL.
FT TRANSMEM 1737 1753 POTENTIAL.
FT TRANSMEM 1775 1791 POTENTIAL.
FT TRANSMEM 1854 1870 POTENTIAL.
FT NP_BIND 933 940 ATP (POTENTIAL).
FT NP_BIND 1946 1953 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 98 98 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 151 151 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 161 161 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 196 196 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 244 244 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 292 292 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 337 337 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 349 349 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 400 400 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 478 478 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 489 489 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 521 521 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 820 820 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1144 1144 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1294 1294 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1453 1453 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1504 1504 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1637 1637 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2044 2044 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2238 2238 N-LINKED (GLCNAC. .) (POTENTIAL).
FT VARIANT 399 399 V -> A (IN TD).
FT VARIANT 587 587 /FTid=VAR_009145.
FT VARIANT 590 590 R -> W (IN TD).
FT VARIANT 590 590 /FTid=VAR_009146.
FT VARIANT 597 597 W -> S (IN TD).
FT VARIANT 597 597 /FTid=VAR_009147.
FT VARIANT 693 693 O -> R (IN TD).
FT VARIANT 693 693 /FTid=VAR_009148.
FT VARIANT 935 935 MISSING (IN TD).
FT VARIANT 935 935 /FTid=VAR_009149.
FT VARIANT 937 937 N -> S (IN TD).
FT VARIANT 937 937 /FTid=VAR_009150.
FT VARIANT 1289 1289 A -> V (IN TD).
FT VARIANT 1289 1289 /FTid=VAR_009151.
FT VARIANT 1477 1477 D -> L (IN TD).
FT VARIANT 1477 1477 /FTid=VAR_009152.
FT VARIANT 1517 1517 C -> R (IN TD).
FT VARIANT 1517 1517 /FTid=VAR_009153.
FT VARIANT 1800 1800 I -> R (IN TD).
FT VARIANT 1800 1800 /FTid=VAR_009154.
FT VARIANT 1800 1800 N -> H (IN TD).

Query Match 100.0%; Score 334; DB 1; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 1.4e-31;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKNNLTFRRQTCOLLEVAWPLFIFILISVRLSVLPYPYEQHECHFPNKA 60
 |||||
 Db 1 MACWPQLRLLLKNNLTFRRQTCOLLEVAWPLFIFILISVRLSVLPYPYEQHECHFPNKA 60

RESULT 2

ID ABC1_MOUSE STANDARD; PRT: 2261 AA.
 AC P41233;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-OCT-2000 (Rel. 40, Last sequence update)
 DE ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 1 (ATP-BINDING CASSETTE
 DE TRANSPORTER 1) (ATP-BINDING CASSETTE 1) (ABC-1).
 GN ABCA1 OR ABC1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 ON NCBI_TaxID=10090;
 [1]
 RC STRAIN-DBA/2; TISSUE-Macrophage;
 RX MEDLINE-94375008; PubMed-8088782;
 RA Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
 RT "Cloning of two novel ABC transporters mapping on human chromosome
 9.";
 RL Genomics 21:150-159(1994).
 RN [2]

SEQUENCE FROM N.A.

RC STRAIN-C57BL/6J;
 RA Qiu Y., Cavellier L., Chiu S., Rubin E., Cheng J.-F.;
 RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies
 identify potential regulatory sequences.";
 RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
 CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
 CC TRANSPORT (BY SIMILARITY).
 CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST
 CC LEVELS ARE FOUND IN PREGNANT UTERUS AND UTERUS.
 CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
 CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
 CC ATP BINDING CASSETTE (ABC) DOMAIN.
 CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
 CC (ABC TRANSPORTERS). MDR SUBFAMILY.

 This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (see <http://www.isb-sib.ch/announce/>;
 or send an email to license@isb-sib.ch).

DR EMBL; X75926; CAA53530.1; ALT_INIT.
 DR EMBL; AF287263; AAC39073.1; ALT_INIT.
 DR MGB; MGI:99607; Abca1.
 DR InterPro; IPR001617; -.
 DR Pfam; PF00005; ABC_tran; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
 KW ATP-binding; Glycoprotein; Transmembrane; Transport.
 FT TRANSMEM 26 42 POTENTIAL.
 FT TRANSMEM 640 656 POTENTIAL.
 FT TRANSMEM 690 706 POTENTIAL.
 FT TRANSMEM 717 733 POTENTIAL.
 FT TRANSMEM 749 765 POTENTIAL.
 FT TRANSMEM 771 787 POTENTIAL.
 FT TRANSMEM 1041 1057 POTENTIAL.
 FT TRANSMEM 1351 1367 POTENTIAL.

FT TRANSMEM 1661 1677 POTENTIAL.
 FT TRANSMEM 1708 1724 POTENTIAL.
 FT TRANSMEM 1737 1753 POTENTIAL.
 FT TRANSMEM 1775 1791 POTENTIAL.
 FT TRANSMEM 1854 1870 POTENTIAL.
 FT NP_BIND 933 940 ATP (POTENTIAL).
 FT NP_BIND 1946 1953 ATP (POTENTIAL).
 FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 98 98 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 151 151 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 161 161 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 196 196 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 244 244 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 292 292 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 337 337 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 349 349 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 400 400 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 478 478 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 489 489 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 521 521 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 820 820 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1144 1144 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1294 1294 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1453 1453 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1499 1499 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1504 1504 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 1637 1637 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 2044 2044 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 2238 2238 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CONFLICT 1567 1568 MISSING (IN REF. 2).
 FT CONFLICT 2024 2024 MISSING (IN REF. 2).
 SQ SEQUENCE 2261 AA; 254011 MW; FAE62B21FD1D09F9 CRC64;

Query Match 100.0%; Score 334; DB 1; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 1.4e-31;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKNNLTFRRQTCOLLEVAWPLFIFILISVRLSVLPYPYEQHECHFPNKA 60
 |||||
 Db 1 MACWPQLRLLLKNNLTFRRQTCOLLEVAWPLFIFILISVRLSVLPYPYEQHECHFPNKA 60

RESULT 3

ABCR_HUMAN STANDARD; PRT: 2273 AA.
 ID ABCR_HUMAN
 AC P78363; O60438; O60915; O15112;
 DT 30-MAY-2000 (Rel. 39, Created)
 DT 30-MAY-2000 (Rel. 39, Last sequence update)
 DT 01-OCT-2000 (Rel. 40, Last annotation update)
 DE RETINAL-SPECIFIC ATP-BINDING CASSETTE TRANSPORTER (RIM ABC
 DE TRANSPORTER) (RIM PROTEIN) (RMP) (STARGARDT DISEASE PROTEIN).
 GN ABCA4 OR ABCR.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 ON NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. AND VARIANTS STGD.
 RX MEDLINE-97207641; PubMed-9054934;
 RA Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A.,
 RA Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A.,
 RA Rattner A., Smallwood P., Li Y., Anderson K.L., Lewis R.A.,
 RA Nathans J., Leppert M., Dean M., Lupski J.R.;
 RT "A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is
 RT mutated in recessive Stargardt macular dystrophy.";
 RL Nat. Genet. 15:236-246(1997).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE-97345663; PubMed-9202155;
 RA Azarian S.M., Travis G.H.;
 RA "The photoreceptor rim protein is an ABC transporter encoded by the
 RT gene for recessive Stargardt's disease (ABCR).";

RL FEBS Lett. 409:247-252(1997).
RN [3]
RP SEQUENCE FROM N.A., AND VARIANTS STGD W-18 AND C-212.
RX MEDLINE-98163759; PubMed-9503029;
RA Gerber S., Rozet J.M., van de Pol T.J.R., Hoying C.B., Munnich A.,
RA Blankenagel A., Kaplan J., Cremers F.P.M.;
RT "Complete exon-intron structure of the retina-specific ATP binding
RT transporter gene (ABCR) allows the identification of novel mutations
RL underlying Stargardt disease.";
RL Genomics 48:139-142(1998).
RN [4]
RP SEQUENCE FROM N.A., AND VARIANTS STGD.
RX MEDLINE-98141133; PubMed-9490294;
RA Nasonkin I., Illing M., Koehler M.R., Schmid M., Molday R.S.,
RA Weber B.H.;
RT "Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1
RT and identification of novel mutations in Stargardt's disease.";
RL Hum. Genet. 102:21-26(1998).
RN [5]
RP CHARACTERIZATION.
RX MEDLINE-99175213; PubMed-10075733;
RA Sun H., Molday R.S., Nathans J.;
RT "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR,
RT the photoreceptor-specific ATP-binding cassette transporter
RT responsible for Stargardt disease.";
RL J. Biol. Chem. 274:8269-8281(1999).
RN [6]
RP VARIANTS ARMD2.
RX MEDLINE-97442530; PubMed-9295268;
RA Allikmets R., Shroyer N.F., Singh N., Seddon J.M., Lewis R.A.,
RA Bernstein P.S., Pellicer A., Zabarskie N.A., Li Y., Hutchinson A.,
RA Dean M., Lupski J.R., Leppert M.;
RT "Mutation of the Stargardt disease gene (ABCR) in age-related macular
RT degeneration.";
RL Science 277:1805-1807(1997).
RN [7]
RP VARIANTS STGD.
RX MEDLINE-98454319; PubMed-9781034;
RA Rozet J.M., Gerber S., Souied E., Perrault I., Chatelin S., Ghazi I.,
RA Leowski C., Dufier J.L., Munnich A., Kaplan J.;
RT "Spectrum of ABCR gene mutations in autosomal recessive macular
RT dystrophies.";
RL Eur. J. Hum. Genet. 6:291-295(1998).
RN [8]
RP VARIANTS STGD.
RX MEDLINE-99138655; PubMed-9973280;
RA Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A.,
RA Li Y., Lupski J.R., Leppert M., Dean M.;
RT "Genotype/phenotype analysis of a photoreceptor-specific ATP-binding
RT cassette transporter gene, ABCR, in Stargardt disease.";
RL Am. J. Hum. Genet. 64:422-434(1999).
RN [9]
RP VARIANTS STGD, AND VARIANTS.
RX MEDLINE-99192348; PubMed-10090887;
RA Maugeri A., van Driel M.A., van de Pol D.J.R., Klevering B.J.,
RA van Haren F.J., Tijmes N., Bergen A.B., Rohrschneider K.,
RA Blankenagel A., Pinckers A.J.L.G., Dahl N., Brunner H.G.,
RA Deutan A.F., Hoying C.B., Cremers F.P.M.;
RT "The 2588G-->C mutation in the ABCR gene is a mild frequent founder
RT mutation in the western European population and allows the
RT classification of ABCR mutations in patients with Stargardt disease.";
RL Am. J. Hum. Genet. 64:1024-1035(1999).
RN [10]
RP VARIANT STGD TYR-54, AND VARIANT ALA-863.
RX MEDLINE-20077755; PubMed-10612508;
RA Zhang K., Garibaldi D.C., Kliazeva M., Albini T., Chiang M.F.,
RA Kerrigan M., Sunness J.S., Han M., Allikmets R.;
RT "A novel mutation in the ABCR gene in four patients with autosomal
RT recessive Stargardt disease.";
RL Am. J. Ophthalmol. 128:720-724(1999).
RN [11]
RP VARIANTS STGD.
RX MEDLINE-20098082; PubMed-10634594;

RA Papaioannou M., Ooka L., Bessant D., Lois N., Bird A., Payne A.,
RA Bhattacharya S.;
RT "An analysis of ABCR mutations in British patients with recessive
RT retinal dystrophies.";
RL Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
CC -1- FUNCTION: MAY PLAY A ROLE IN PHOTORESPONSE. RETINOIDS, AND MOST
CC LIKELY RETINAL, ARE THE NATURAL SUBSTRATES FOR TRANSPORT BY ABCR
CC IN ROD OUTER SEGMENTS. MAY ACT IN THE VISUAL CYCLE TO FLIP PE-ALL-
CC TRANS-RETINAL ADDUCTS FROM THE LUMENAL TO THE CYTOSOLIC FACE OF
CC THE DISC MEMBRANE, MOVE FREE ALL-TRANS-RETINAL FROM THE LIPID
CC PHASE OF THE DISC MEMBRANE TO A JUXTAMEMBRANE LOCATION, OR
CC POSSIBLY REORIENT ALL-TRANS-RETINAL IN THE BILAYER.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.
CC -1- TISSUE SPECIFICITY: RETINAL-SPECIFIC. SEEMS TO BE EXCLUSIVELY
CC FOUND IN THE RIMS OF ROD PHOTORECEPTOR CELLS.
CC -1- DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF STARGARDT DISEASE (STGD);
CC ALSO KNOWN AS FUNDUS FLAVIMACULATUS (FFM) OR JUVENILE-ONSET MACULAR
CC DEGENERATION. IT IS AN AUTOSOMAL RECESSIVE RETINAL DISORDER. IT IS
CC ONE OF THE MOST FREQUENT CAUSES OF MACULAR DEGENERATION IN
CC CHILDHOOD. IT IS CHARACTERIZED BY A JUVENILE-ONSET MACULAR
CC DYSTROPHY, ALTERATIONS OF THE PERIPHERAL RETINA, AND SUBRETINAL
CC DEPOSITION OF LIPOFUSCIN-LIKE MATERIAL.
CC -1- DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF AGE-RELATED MACULAR
CC DEGENERATION (ARMD2 OR AMD).
CC -1- DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF AUTOSOMAL RECESSIVE CONE-
CC ROD DYSTROPHY (ARCRD OR CRD).
CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS).
CC -1- DATABASE: NAME=Mutations of the ABCA4 gene;
CC NOTE=Retina International's Scientific Newsletter;
CC WWW="http://www.irpa.org/sci-news/abcrmut.htm".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U88667; AAC51144.1;
DR EMBL; AF000148; AAC23915.1;
DR EMBL; Y15635; CAA75729.1; JOINED.
DR EMBL; Y15636; CAA75729.1; JOINED.
DR EMBL; Y15637; CAA75729.1; JOINED.
DR EMBL; Y15638; CAA75729.1; JOINED.
DR EMBL; Y15639; CAA75729.1; JOINED.
DR EMBL; Y15640; CAA75729.1; JOINED.
DR EMBL; Y15641; CAA75729.1; JOINED.
DR EMBL; Y15642; CAA75729.1; JOINED.
DR EMBL; Y15643; CAA75729.1; JOINED.
DR EMBL; Y15644; CAA75729.1; JOINED.
DR EMBL; Y15645; CAA75729.1; JOINED.
DR EMBL; Y15646; CAA75729.1; JOINED.
DR EMBL; Y15647; CAA75729.1; JOINED.
DR EMBL; Y15648; CAA75729.1; JOINED.
DR EMBL; Y15649; CAA75729.1; JOINED.
DR EMBL; Y15650; CAA75729.1; JOINED.
DR EMBL; Y15651; CAA75729.1; JOINED.
DR EMBL; Y15652; CAA75729.1; JOINED.
DR EMBL; Y15653; CAA75729.1; JOINED.
DR EMBL; Y15654; CAA75729.1; JOINED.
DR EMBL; Y15655; CAA75729.1; JOINED.
DR EMBL; Y15656; CAA75729.1; JOINED.
DR EMBL; Y15657; CAA75729.1; JOINED.
DR EMBL; Y15658; CAA75729.1; JOINED.
DR EMBL; Y15659; CAA75729.1; JOINED.
DR EMBL; Y15660; CAA75729.1; JOINED.
DR EMBL; Y15661; CAA75729.1; JOINED.
DR EMBL; Y15662; CAA75729.1; JOINED.
DR EMBL; Y15663; CAA75729.1; JOINED.
DR EMBL; Y15664; CAA75729.1; JOINED.
DR EMBL; Y15665; CAA75729.1; JOINED.

DR EMBL; Y15666; CAA75729.1; JOINED.
 DR EMBL; Y15667; CAA75729.1; JOINED.
 DR EMBL; Y15668; CAA75729.1; JOINED.
 DR EMBL; Y15669; CAA75729.1; JOINED.
 DR EMBL; Y15670; CAA75729.1; JOINED.
 DR EMBL; Y15671; CAA75729.1; JOINED.
 DR EMBL; Y15672; CAA75729.1; JOINED.
 DR EMBL; Y15673; CAA75729.1; JOINED.
 DR EMBL; Y15674; CAA75729.1; JOINED.
 DR EMBL; Y15675; CAA75729.1; JOINED.
 DR EMBL; Y15676; CAA75729.1; JOINED.
 DR EMBL; Y15677; CAA75729.1; JOINED.
 DR EMBL; Y15678; CAA75729.1; JOINED.
 DR EMBL; Y15679; CAA75729.1; JOINED.
 DR EMBL; Y15680; CAA75729.1; JOINED.
 DR EMBL; Y15681; CAA75729.1; JOINED.
 DR EMBL; Y15682; CAA75729.1; JOINED.
 DR EMBL; Y15683; CAA75729.1; JOINED.
 DR EMBL; Y15684; CAA75729.1; JOINED.
 DR EMBL; AF001945; AAC05632.1; -.
 DR MIM; 601691; -.
 DR MIM; 248200; -.
 DR MIM; 153800; -.
 DR InterPro; IPR001617; -.
 DR Pfam; PF00005; ABC_tran; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER; 1.

Query Match 53.9%; Score 180; DB 1; Length 2273;
 Best Local Similarity 56.4%; Pred. No. 1.8e-13;
 Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

Oy 6 QLRLLLNLTFRRTQCLLEVAWPLFELILISVRLSYPEYQHECHFPNKA 60
 Db 6 QQLLKNWTKRKQKRFVVELVWPLSLFLVLWLRNANPLYSHECHFPNKA 60

RESULT 4
 ID ABC3_HUMAN STANDARD; PRT; 1704 AA.
 AC Q99758; Q92473;
 DT 30-MAY-2000 (Rel. 39, Created)
 DT 30-MAY-2000 (Rel. 39, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 3 (ATP-BINDING CASSETTE
 DE TRANSPORTER 3) (ATP-BINDING CASSETTE 3) (ABC-C TRANSPORTER).
 GN ABC3 OR ABC3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Thyroid carcinoma;
 RX MEDLINE=96326608; PubMed=8706931;
 RA Klugbauer N., Hofmann F.;
 RT "Primary structure of a novel ABC transporter with a chromosomal
 RT localization on the band encoding the multidrug resistance-associated
 RT protein.";
 RL FEBS Lett. 391:61-65(1996).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=97179225; PubMed=9027511;
 RA Connors T.D., van Raay T.J., Petry L.R., Klinger K.W., Landes G.M.,
 RA Burn T.C.;
 RT "The cloning of a human ABC gene (ABC3) mapping to chromosome
 RT 16p13.3.";
 RL Genomics 39:231-234(1997).
 CC -1- FOUND YET MAY BE A TRANSPORTER. ITS NATURAL SUBSTRATE HAS NOT BEEN
 CC IDENTIFIED (BY SIMILARITY). MAY ACT AS AN EFFLUX PUMP FOR
 CC CHEMOTHERAPEUTICS DRUGS.
 CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN LUNG, FOLLOWED BY BRAIN.
 CC PANCREAS, SKELETAL MUSCLE AND HEART. WEAKLY EXPRESSED IN PLACENTA,
 CC KIDNEY AND LIVER. ALSO EXPRESSED IN MEDULLARY THYROID CARCINOMA

CC CELLS (MTC) AND IN C-CELL CARCINOMA.
 CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
 CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
 CC ATP BINDING CASSETTE (ABC) DOMAIN (BY SIMILARITY).
 CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
 CC (ABC TRANSPORTERS). MDR SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; U78735; AAC50967.1; -.
 DR EMBL; X97187; CAA05825.1; -.
 DR MIM; 601615; -.
 DR InterPro; IPR001617; -.
 DR Pfam; PF00005; ABC_tran; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
 KW ATP-binding; transport; transmembrane.
 FT TRANSMEM 22 42 POTENTIAL.
 FT TRANSMEM 249 269 POTENTIAL.
 FT TRANSMEM 307 327 POTENTIAL.
 FT TRANSMEM 344 364 POTENTIAL.
 FT TRANSMEM 373 393 POTENTIAL.
 FT TRANSMEM 405 425 POTENTIAL.
 FT TRANSMEM 447 467 POTENTIAL.
 FT TRANSMEM 925 945 POTENTIAL.
 FT TRANSMEM 1100 1120 POTENTIAL.
 FT TRANSMEM 1144 1164 POTENTIAL.
 FT TRANSMEM 1183 1203 POTENTIAL.
 FT TRANSMEM 1213 1233 POTENTIAL.
 FT TRANSMEM 1245 1265 POTENTIAL.
 FT TRANSMEM 1306 1326 POTENTIAL.
 FT NP_BIND 566 573 ATP (POTENTIAL).
 FT NP_BIND 1416 1423 ATP (POTENTIAL).
 FT NP_BIND 1416 1423 P -> S (IN REF. 2).
 FT CONFLICT 196 196 L -> P (IN REF. 2).
 FT CONFLICT 196 196 L -> P (IN REF. 2).
 SQ SEQUENCE 1704 AA; 191387 MW; AF0098DAF7A04F5F CRC64;
 Query Match 25.1%; Score 84; DB 1; Length 1704;
 Best Local Similarity 47.7%; Pred. No. 0.026;
 Matches 21; Conservative 6; Mismatches 17; Indels 0; Gaps 0;
 Oy 1 MACWPQLRLNLKNTFRRTQCLLEVAWPLFELILISVRL 44
 Db 1 MAVLRQLALLLNKNTLQKRRVLTVELFLPLFPGLIWLRL 44
 RESULT 5
 ID FTSK_COXBU STANDARD; PRT; 778 AA.
 AC F39920;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, Last sequence update)
 DT 01-NOV-1997 (Rel. 35, Last annotation update)
 DE CELL DIVISION PROTEIN FTSK HOMOLOG.
 GN FTSK OR SPOIIE.
 OS Coxiella burnetii.
 OC Bacteria; Proteobacteria; gamma subdivision; Legionellaceae group;
 OC Coxiella group; Coxiella.
 OX NCBI_TaxID=77;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NINE MILE PHASE I / BRATISLAVA;
 RX MEDLINE=94055499; PubMed=8237209;
 RA Oswald W., Thiele D.;
 RT "A sporulation gene in Coxiella burnetii?";
 RL J. Vet. Med. B 40:366-370(1993).
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN (POTENTIAL).


```

RESULT      8
SYV_NEUCR
ID          SYV_NEUCR      STANDARD;      PRT: 1093 AA.
AC          P28350;
DT          01-DEC-1992 (Rel. 24, Created)
DT          01-DEC-1992 (Rel. 24, Last sequence update)
DT          30-MAY-2000 (Rel. 39, Last annotation update)
DE          VALYL-TRNA SYNTHETASE, MITOCHONDRIAL PRECURSOR (EC 6.1.1.9)
DE          (VALINE--TRNA LIGASE) (VALRS).
GN          CYT-20 OR UN-3.
OS          Neurospora crassa.
OC          Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC          Sordariales; Sordariaceae; Neurospora.
NCBI_TaxID=5141;
[1]
SEQUENCE FROM N.A.
RC          STRAIN=74-OR23-1A;
RX          MEDLINE=91304394; PubMed=1830127;
RA          Kubelik A.R., Turcok B., Lambowitz A.M.;
RT          "The Neurospora crassa cyt-20 gene encodes cytosolic and
RT          mitochondrial valyl-tRNA synthetases and may have a second function
RT          in addition to protein synthesis.";
RL          Mol. Cell. Biol. 11:4022-4035(1991).
CC          -1- FUNCTION: MAY HAVE A SECOND FUNCTION IN ADDITION TO PROTEIN
CC          SYNTHESIS.
CC          -1- CATALYTIC ACTIVITY: ATP + L-VALINE + TRNA(VAL) = AMP +
CC          PYROPHOSPHATE + L-VALYL-TRNA(VAL).
CC          -1- SUBCELLULAR LOCATION: MITOCHONDRIAL CYTOPLASMIC.
CC          -1- ALTERNATIVE PRODUCTS: A SINGLE NUCLEAR GENE PRODUCES BOTH FORMS
CC          BY USE OF ALTERNATIVE INITIATION CODONS IN THE SAME READING FRAME.
-----
CC          THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC          between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC          the European Bioinformatics Institute. There are no restrictions on its
CC          use by non-profit institutions as long as its content is in no way
CC          modified and this statement is not removed. Usage by and for commercial/
CC          entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC          or send an email to license@isb-sib.ch).
-----

```

CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announcement/>
CC or send an email to license@isb-sib.ch).

ENBL; U95958; AAB53864.1; -.
HSP; Q02846; IAWL.
InterPro: IPR000719; -.
InterPro: IPR01054; -.
InterPro: IPR001828; -.
Pfam: PFO1094; ANF_receptor; 1.
Pfam: PFO0069; pkinase; 1.
PROSITE; PS00452; GUANYLATE_CYCLASES_1; 1.
PROSITE; PS00135; GUANYLATE_CYCLASES_2; 1.
PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
Lysase; cGMP synthesis; Signal; Transmembrane; Multigene family;
Vision.

FT	SIGNAL	1	46	BY SIMILARITY.
FT	CHAIN	47	1103	RETINAL GUANYLYL CYCLASE 2.
FT	DOMAIN	47	465	EXTRACELLULAR (POTENTIAL).
FT	TRANSMEM	466	490	POTENTIAL.
FT	DOMAIN	491	1103	CYTOPLASMIC (POTENTIAL).
FT	DOMAIN	524	810	PROTEIN KINASE-LIKE.
FT	DOMAIN	813	1064	CATALYTIC.
FT	DISULFID	104	132	BY SIMILARITY.
FT	DISULFID	452	452	INTERCHAIN (PROBABLE).
FT	DISULFID	460	460	INTERCHAIN (PROBABLE).
SQ	SEQUENCE	1103 AA;	124361 MW;	EB731E1D8C642AA4 CRC64;

Query Match 17.1%; Score 57; DB 1; Length 1103;
Best Local Similarity 34.0%; Pred. No. 26;
Matches 18; Conservative 11; Mismatches 20; Indels 4; Gaps 3;

Qy	1 MACWPQLRLLW-KNLTFRRRQTCLLLEVAWPLFIFLIILSVRLSY--PPYE 50 : : - : :: : : : :
Db	3 LAPWPFSLMLWFVTLGRQGQHGLASTKLLWCWL-LVIMSLPQVWAPPYK 54

RESULT	10
Y563_HUMAN	
ID	Y563_HUMAN
STANDARD;	PRT; 870 AA.
AC	O60309;
DT	01-OCT-2000 (Rel. 40, Created)
DT	01-OCT-2000 (Rel. 40, Last sequence update)
DT	01-OCT-2000 (Rel. 40, Last annotation update)
DE	HYPOTHETICAL PROTEIN KIAA0563.
GN	KIAA0563.
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Brain;
RC	MEDLINE=98290545; PubMed=9628581;
RX	Nagase T., Ishikawa K.-I., Miyajima N., Tanaka A., Kotani H.,
RA	Nomura N., Ohara O.;
RA	"Prediction of the coding sequences of unidentified human genes. IX.
RT	The complete sequences of 100 new cDNA clones from brain which can
RT	code for large proteins in vitro."
RL	DNA Res. 5:31-39(1998).

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; AB011135; BAA25489.1; -
Hypothetical protein.
KW SEQUENCE 870 AA; 94665 MW; BD76CD70A005FA96 CRC64;
SQ

Query Match	16.9%	Score	56.5	DB	1	Length	870
Best Local Similarity	34.4%	Pred. No.	24				
Matches	21	Conservative	6	Mismatches	19	Indels	15
Gaps							4

QY	4	WPQLRLLLWKNLFRRRQTCQLLELVAMPLEIF---	LILISVRLSY-PYEQHECHFPNK	59
		:		
Db	22	WP-----LLMW-----QLLWLLVKEAQLPEWKDPQLQLT	SNPLGPPPEPWSHSHHPRE	70
QY	60	A	60	
		:		
Db	71	S	71	

```

RESULT 11
D5DR_FUGRU D5DR_FUGRU STANDARD; PRT; 463 AA.
ID AC P53454;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE D(5)-LIKE DOPAMINE RECEPTOR.
DL
GN
OS Fugu rubripes (Japanese pufferfish) (Takifugu rubripes).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acantopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontidae; Takifugu.
OC NCBI_TaxID=31033;

```

[1]
RN SEQUENCE FROM N.A.
RP MEDLINE=95309911; PubMed=7789977;
RA Machae A.D.; Brenner S.;
RT "Analysis of the dopamine receptor family in the compact genome of
the puffer fish *Fugu rubripes*.";
RL Genomics 25:436-446(1995).
CC -!- FUNCTION: RECEPTOR FOR DOPAMINE.
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.
CC -!- SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/) or send an email to license@sib-sb.ch)

CC	
DR	EMBL; X80177; CAA56457.1; -.
DR	GCRDB; GCR_1105; -.
DR	InterPro; IPR000276; --
DR	InterPro; IPR000929; --
DR	Pfam; PF00001; 7tm1_1; 1.
DR	PRINTS; PR00237; GPCRRHODOPSN.
DR	PRINTS; PR00242; DOPAMINER.
DR	PROSITE; PS00337; G_PROTEIN_RECEP_F1_1; 1.
DR	PROSITE; PS00362; G_PROTEIN_RECEP_F1_2; 1.
KW	G-protein coupled receptor; Transmembrane; Glycoprotein;
KW	Multigene family.
FT	DOMAIN 1 39
FT	TRANSMEM 40 65 EXTRACELLULAR (POTENTIAL).
FT	DOMAIN 66 76 1 (POTENTIAL).
FT	TRANSMEM 77 103 CYTOPLASMIC (POTENTIAL).
FT	DOMAIN 104 112 2 (POTENTIAL).
FT	TRANSMEM 113 135 EXTRACELLULAR (POTENTIAL).
FT	DOMAIN 136 154 3 (POTENTIAL).
FT	TRANSMEM 155 180 CYTOPLASMIC (POTENTIAL).
FT	DOMAIN 181 198 4 (POTENTIAL).
FT	TRANSMEM 199 223 EXTRACELLULAR (POTENTIAL).
FT	DOMAIN 224 273 5 (POTENTIAL).
FT	TRANSMEM 274 301 6 (POTENTIAL).
FT	DOMAIN 302 315 EXTRACELLULAR (POTENTIAL).


```
FT TRANSMEM 316 337 7 (POTENTIAL).
FT DOMAIN 338 463 CYNOLASMIC (POTENTIAL).
FT CARBOHYD 6 6 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT DISULFID 112 194 BY SIMILARITY.
SQ SEQUENCE 463 AA: 51095 MW: 7FD627F69A699F6B CRC64;

Query Match 16.8%; Score 56; DB 1; Length 463;
Best Local Similarity 28.6%; Pred. No. 16;
Matches 14; Conservative 12; Mismatches 13; Indels 10; Gaps 2;

QY 17 FRRRTQCG---LLLEVAMPFLFLILISVRLSY-----PPVEQHECH 55
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 147 YERRMTRRAFLMIAVANTLVLSIPVQLNHRADNNSAHEQDGN 195
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 12
CN2A_BOVIN STANDARD; PRT; 921 AA.
AC P14099; Q28064;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (EC 3.1.4.17)
DE (CYCLIC GMP STIMULATED PHOSPHODIESTERASE) (CGS-PDE).
GN PDE2A.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A. (PDE2A1).
RX MEDLINE-91373395; PubMed-1654333;
RA Sonnenburg W.K., Mullaney P.J., Beavo J.A.;
RT "Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide
RT phosphodiesterase cDNA. Identification and distribution of isozyme
RT variants."
RL J. Biol. Chem. 266:17655-17661(1991).
RN [2]
RP SEQUENCE FROM N.A. (PDE2A3).
RX MEDLINE-91104948; PubMed-2176866;
RA le Trong H., Beier N., Sonnenburg W.K., Stroop S.D., Walsh K.A.,
RA Beavo J.A., Charbonneau H.;
RT "Amino acid sequence of the cyclic GMP stimulated cyclic nucleotide
RT phosphodiesterase from bovine heart."
RL Biochemistry 29:10280-10288(1990).
RN [4]
RP SEQUENCE OF 613-694 AND 808-868.
RT TISSUE=Heart;
RX MEDLINE-87092242; PubMed-3025833;
RA Charbonneau H., Beier N., Walsh K.A., Beavo J.A.;
RT "Identification of a conserved domain among cyclic nucleotide
RT phosphodiesterases from diverse species."
RL Proc. Natl. Acad. Sci. U.S.A. 83:9308-9312(1986).
CC -1- CATALYTIC ACTIVITY: GUANOSINE 3',5'-CYCLIC PHOSPHATE + H(2)O -
CC GUANOSINE 5'-PHOSPHATE.
CC -1- SUBUNIT: HOMODIMER.
CC -1- SUBCELLULAR LOCATION: MEMBRANE-BOUND (POTENTIAL).
CC HERE), PDE2A2 AND PDE2A3; ARE PRODUCED BY ALTERNATIVE SPLICING.
CC -1- SIMILARITY: BELONGS TO THE CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
CC FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
CC EMBL; M73512; AAA74559.1; -
CC EMBL; L49503; AAA87353.1; -
CC PIR; A40981; A40981.
CC InterPro: IPR002073; -
CC InterPro: IPR003018; -
CC Pfam; PF01590; GAF; 2.
CC Pfam; PF00233; PDEase; 1.
CC PRINTS; PR00387; PDIESTERASE1.
CC PROSITE; PS00126; PDEASE.1; 1.
KW Hydrolase; cGMP; Alternative splicing; Membrane; Acetylation.
FT MOD_RES 1 1 ACETYLATION.
FT DOMAIN 613 871
FT VARSPPLIC 1 25
FT FT
FT FT
FT FT
FT FT
FT FT
SQ SEQUENCE 921 AA: 103227 MW: E29F4C9875E83640 CRC64;

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 29;
Matches 17; Conservative 6; Mismatches 19; Indels 4; Gaps 1;

QY 3 CWPQLRLLMKNTFRRRQ-----TCQLLLEVAMPFLFLILISVRL 44
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 349 CFHYTSTVLTSLAFQEKLKCECQALLQVAKNLFTHLDDVSLL 394
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 13
CN2A_HUMAN STANDARD; PRT; 941 AA.
AC O00408;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 01-OCT-2000 (Rel. 40, Last annotation update)
DE CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (EC 3.1.4.17)
DE (CYCLIC GMP STIMULATED PHOSPHODIESTERASE) (CGS-PDE).
GN PDE2A.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE-97354299; PubMed-9210593;
RA Rosman G.J., Martins T.J., Sonnenburg W.K., Beavo J.A., Ferguson K.,
RA Loughney K.;
RT "Isolation and characterization of human cDNAs encoding a cGMP-
RT stimulated 3',5'-cyclic nucleotide phosphodiesterase."
RL Gene 191:89-95(1997).
CC -1- CATALYTIC ACTIVITY: GUANOSINE 3',5'-CYCLIC PHOSPHATE + H(2)O -
CC GUANOSINE 5'-PHOSPHATE.
CC -1- SUBUNIT: HOMODIMER (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: MEMBRANE-BOUND (POTENTIAL).
CC -1- ALTERNATIVE PRODUCTS: AT LEAST 3 ISOFORMS: PDE2A1, PDE2A2 AND
CC PDE2A3 (SHOWN HERE); ARE PRODUCED BY ALTERNATIVE SPLICING.
CC -1- SIMILARITY: BELONGS TO THE CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
CC FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
```


SQ SEQUENCE 436 AA; 51340 MW; 58051BFE59A4555F CRC64;

 Query Match 16.6%; Score 55.5; DB 1; Length 436;
 Best Local Similarity 27.3%; Pred.No.17;
 Matches 12; Conservative 10; Mismatches 21; Indels 1; Gaps 1;

 QY 14 NLTRFRRTQCLLLEAVMPL-FIFILILISVRLSYPPYEHCHECF 56
 :l:l :l:l :l:l :l:l :l:l :l:l :l:l :l:l :l:l
 Db 62 NITISTRATLYDQGVTDSPAIKFTLCQIDVRWFPDEQNCHF 105

 RESULT 15
 AT\$4_HUMAN STANDARD; PRT; 837 AA.
 AC 075173; Q9UN83;
 DT 01-OCT-2000 (Rel. 40, Created)
 DT 01-OCT-2000 (Rel. 40, Last sequence update)
 DE ADAM-TS 4 PRECURSOR (EC 3.4.24.-) (A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 4) (ADAMTS-4) (ADAM-TS4) (AGGREGANASE 1) (ADMP-1).
 DE (ADMP-1).
 GN ADAMTS4 OR KIA0688.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=98403880; PubMed=9734811;
 RA Ishikawa K.-I., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
 RT "Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.";
 RL DNA Res. 5:169-176(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99286303; PubMed=10356395;
 RA Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M., Liu R., Rosenfeld S.A., Copeland R.A., Decicco C.P., Wynn R., Rackwell A., Yang F., Duke J.L., Solomon K., George H., Bruckner R., Kagawa H., Itoh Y., Ellis D.M., Ross H., Wiswall B.H., Murphy K., Hillman M.C. Jr., Hollis G.F., Newton R.C., Magolda R.L., Trzaskos J.M., Arner E.C.;
 RT "Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteases.";
 RL Science 284:1664-1666(1999).
 RN [3]
 RP PARTIAL SEQUENCE, AND CHARACTERIZATION.
 RX MEDLINE=20400518; PubMed=10827174;
 RA Tortorella M., Pratta M., Liu R.O., Abbaszade I., Ross H., Burn T., Arner E.;
 RT "The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage.";
 RL J. Biol. Chem. 275:25791-25797(2000).
 CC -!- FUNCTION: CLEAVES AGGREGAN, A CARTILAGE PROTEOGLYCAN, AND MAY BE INVOLVED IN ITS TURNOVER. MAY PLAY AN IMPORTANT ROLE IN THE DESTRUCTION OF AGGREGAN IN ARTHRITIC DISEASES.
 CC -!- CATALYTIC ACTIVITY: CLEAVES AGGREGAN AT THE 392-GLU-|-ALA-393 SITE.
 CC -!- COFACTOR: BINDS ONE ZINC ION (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: SECRETED. ASSOCIATED WITH THE EXTRACELLULAR MATRIX (BY SIMILARITY).
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN BRAIN, LUNG AND HEART. EXPRESSED AT VERY LOW LEVEL IN PLACENTA AND SKELETAL MUSCLES.
 CC -!- INDUCTION: BY INTERLEUKIN 1.
 CC -!- DOMAIN: THE SPACER DOMAIN AND THE TSP TYPE 1 DOMAINS ARE IMPORTANT FOR A RIGHT INTERACTION WITH THE EXTRACELLULAR MATRIX.
 CC -!- PTM: THE PRECURSOR IS CLEAVED BY A FUIN ENDOPEPTIDASE.
 CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M12B (ZINC METALLOPROTEASE); ALSO KNOWN AS THE REPROLYSIN SUBFAMILY

```

Query Match      16.6%; Score 55.5; DB 1; Length 837;
Best Local Similarity 32.6%; Pred. No. 31;
Matches 15; Conservative 10; Mismatches 14; Indels 7; Gaps 2;

QY 21 QTCOLL--LGVAMPFLFLILI-----SVRLSPYPYEQHECHFPNK 59
      ||| : : : : : ||| : : : : : |||
DB 21 QPCLLPIPVLSLWMLLLLLLLASLPSARLASPLPREEEIVFPKEK 66
      ||| : : : : : ||| : : : : : |||

```

Search completed: May 31, 2001, 13:08:58
Job time: 299 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:19:49 ; Search time 39.12 Seconds
(without alignments)
105.403 Million cell updates/sec

Title: US-09-526-193A-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKWLTKRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 198801 seqs, 68722935 residues

Total number of hits satisfying chosen parameters: 198801

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_67:*

- 1: pir1:*
- 2: pir2:*
- 3: pir3:*
- 4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	86	25.7	1704	2 S71363	probable ATP-bind
2	84	25.1	1704	2 A59188	ATP-binding casset
3	71.5	21.4	707	2 T09340	hypothetical prote
4	65.5	19.6	778	2 S43132	sporulation protei
5	60.5	18.1	511	2 T43634	nicotinic acetylch
6	60.5	18.1	534	2 T23720	hypothetical prote
7	60.5	18.1	598	2 T05130	hypothetical prote
8	60	18.0	1802	2 T33783	hypothetical prote
9	59.5	17.8	466	2 PC4296	nicotinic acetylch
10	58.5	17.5	383	2 T07688	omega-6 desaturase
11	58	17.4	250	2 D75317	hypothetical prote
12	57	17.1	1093	2 A41251	valine--trNA ligas
13	57	17.1	1103	2 JC5581	guanylate cyclase
14	56.5	16.9	1400	2 T22644	hypothetical prote
15	56.5	16.9	1977	2 S54771	sodium channel alp
16	56.5	16.9	3268	2 S69625	hypothetical prote
17	56	16.8	373	2 JC7289	G-protein coupled
18	56	16.8	463	2 B56849	dopamine receptor-
19	56	16.8	512	2 H81938	probable apolipop
20	56	16.8	524	2 E81166	apolipoprotein N-a
21	56	16.8	830	2 T04848	protein kinase hom
22	56	16.8	921	1 A40981	3',5'-cyclic-nucle
23	56	16.8	1215	2 B72029	helicase, Snf2/Rad
24	56	16.8	2201	2 A54774	ATP binding casset
25	55.5	16.6	299	2 F83301	conserved hypothet
26	55.5	16.6	372	2 T20289	hypothetical prote
27	55.5	16.6	378	2 T14269	delta12 fatty acid
28	55.5	16.6	495	2 G70852	hypothetical prote
29	55.5	16.6	706	2 T20052	hypothetical prote

30	55.5	16.6	837	2 T00355	hypothetical prote
31	55	16.5	293	2 T32229	hypothetical prote
32	55	16.5	357	2 H64855	probable membrane
33	55	16.5	928	1 JC2486	3',5'-cyclic-nucle
34	55	16.5	1976	2 I56555	sodium channel pro
35	54.5	16.3	383	2 T10480	Delta12 fatty acid
36	54.5	16.3	454	2 T32974	hypothetical prote
37	54	16.2	401	2 B83369	conserved hypothet
38	54	16.2	442	2 A83743	magnesium citrate
39	54	16.2	547	2 S61032	hypothetical prote
40	54	16.2	825	2 T27852	hypothetical prote
41	54	16.2	2005	2 B25019	sodium channel alp
42	54	16.2	2005	2 A46269	sodium channel alp
43	53.5	16.0	333	2 I65989	G protein-coupled
44	53.5	16.0	538	2 D82180	probable sensor ki
45	53.5	16.0	778	2 T05341	S-receptor kinase

ALIGNMENTS

RESULT 1

S71363

Probable ATP-binding cassette transporter ABC-3 - human

N;Alternate names: ATP-binding cassette transporter ABC-C

C;Species: Homo sapiens (man)

C;Date: 29-Jan-1998 #sequence_revision 06-Feb-1998 #text_change 17-Mar-2000

C;Accession: S71363

R;Klugbauer, N.; Hofmann, F.

FEBS Lett. 391, 61-65, 1996

A;Title: Primary structure of a novel ABC transporter with a chromosomal localization

A;Reference number: S71363; MUID:96326608

A;Accession: S71363

A;Status: nucleic acid sequence not shown

A;Molecule type: mRNA

A;Residues: 1-1704 <KLU>

A;Cross-references: EMBL:X97187; NID:q1514529; PIDN:CAA65825.1; PID:e243436; PID:q151

A;Experimental source: cell line medullary thyroid carcinoma

C;Genetics:

A;Gene: GDB:ABC3

A;Cross-references: GDB:3770735; OMIM:601615

A;Map position: 16p13.3-16p13.3

C;Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog

C;Keywords: ATP binding; P-loop; phosphoprotein; transmembrane protein

F;255-283/Domain: transmembrane #status predicted <TM1>

F;307-329/Domain: transmembrane #status predicted <TM2>

F;345-364/Domain: transmembrane #status predicted <TM3>

F;373-394/Domain: transmembrane #status predicted <TM4>

F;401-422/Domain: transmembrane #status predicted <TM5>

F;452-475/Domain: transmembrane #status predicted <TM6>

F;549-739/Domain: ATP-binding cassette homolog <ABC1>

F;566-573/Region: nucleotide-binding motif A (P-loop)

F;685-690/Region: nucleotide-binding motif B

F;1100-1120/Domain: transmembrane #status predicted <TM7>

F;1145-1169/Domain: transmembrane #status predicted <TM8>

F;1181-1207/Domain: transmembrane #status predicted <TM9>

F;1215-1236/Domain: transmembrane #status predicted <TM10>

F;1245-1264/Domain: transmembrane #status predicted <TM11>

F;1299-1324/Domain: transmembrane #status predicted <TM12>

F;1399-1590/Domain: ATP-binding cassette homolog <ABC2>

F;1416-1423/Region: nucleotide-binding motif A (P-loop)

F;1535-1540/Region: nucleotide-binding motif B

F;674,866,1524/Binding site: phosphate (Ser) (covalent) (by CAMP-dependent kinase) #s

F;1344/Binding site: phosphate (Thr) (covalent) (by CAMP-dependent kinase) #status pr

Query Match 25.7%; Score 86; DB 2; Length 1704;

Best Local Similarity 47.7%; Pred. No. 0.016;

Matches 21; Conservative 6; Mismatches 17; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLLKWLTKRRRQCQLLEVAWPLFLILISVRL 44

Db 1 MAVLRQALLLWKNTYQKRKVLTVLEFLPLFSGILWRL 44

RESULT 2

A59188
ATP-binding cassette transporter ABC3 - human
C:Species: Homo sapiens (man)
C:Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 04-Mar-2000
C:Accession: A59188
R:Connors, T.D.; van Raay, T.J.; Petry, L.R.; Klinger, K.W.; Landes, G.M.; Burn, T.C.
Genomics 39, 231-234, 1997
A:Title: The cloning of a human ABC gene (ABC3) mapping to chromosome 16p13.3.
A:Reference number: A59188; MUID:97179225
A:Accession: A59188
A>Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-1704 <CON>
A:Cross-references: GB:U78735; NID:g1699037; PIDN:AAC50967.1; PID:g1699038
C:Genetics:
A:Gene: GDB:ABC3
A:Cross-references: GDB:3770735; OMIM:601615
A:Map position: 16p13.3-16p13.3
C:Superfamily: ATP-binding cassette homology

Query Match 25.1%; Score 84; DB 2; Length 1704;
Best Local Similarity 47.7%; Pred. No. 0.028;
Matches 21; Conservative 6; Mismatches 17; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKNTLFTERRTOTCOLLEVAWPLFIFILISVRL 44
|| || || || || || | :||: || ||| :||
Db 1 MAVLRQLALLLNKNYTLQKKVLVTVLELPFLPLPGILLWLRL 44

RESULT 3

T09340
hypothetical protein T26M18.20 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 22-Oct-1999
C:Accession: T09340
R:Bavan, M.; Hilbert, H.; Braun, M.; Holzer, E.; Brandt, A.; Duesterhoeft, A.; Bancro
submitted to the Protein Sequence Database, June 1999
A:Reference number: Z16650
A:Accession: T09340
A:Molecule type: DNA
A:Residues: 1-707 <BEV>
A:Cross-references: EMBL:AL078606; GSPDB:GN00062; ATSP:T26M18.20
A:Experimental source: cultivar Columbia; BAC clone T26M18
C:Genetics:
A:Gene: ATSP:T26M18.20
A:Map position: 4
A:Introns: 18/2; 58/3; 162/3; 197/3; 354/2; 455/1; 520/3; 584/2; 629/1

Query Match 21.4%; Score 71.5; DB 2; Length 707;
Best Local Similarity 36.7%; Pred. No. 0.43;
Matches 22; Conservative 7; Mismatches 24; Indels 7; Gaps 2;

Qy 1 MACWPQLRLLLW-----KNLTFRRRQTCCOLLLEVAWPLFIFILISVRLSYPPYEQEHECH 55
||| || || || || || :||: ||| :||: ||| :||
Db 390 MACGPALAGLIQTDFKKNVTFNQDTLPGVMMAVANLLYLWLAISPR--EPAREPEIHH 447

RESULT 4

S43132
sporulation protein spoIIIE - Coxiella burnetii
C:Species: Coxiella burnetii
C:Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 08-Oct-1999
C:Accession: S43132; S31759
R:Oswald, W.
submitted to the EMBL Data Library, November 1993
A:Reference number: S43131
A:Accession: S43132
A:Molecule type: DNA

A; Molecule type: DNA

QY 14 NLTFRRRQTCQLLEVAW-PLFIFILISVRLSPYPPEQHECH 55

K, MILEY, L.O.O., NE-

A: Molecule type

C/ACCESSION: PC4296
R;WILEY, L.J.; WEISS, A.S.; SANGSTER, N.C.; LI, Q.

Search completed: May 31, 2001, 13:05:24
Job time: 2735 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run On: May 31, 2001, 13:03:19 ; Search time 54.28 seconds
(without alignments)
14.331 Million cell updates/sec

Title: US-09-526-193a-l_copy_l_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKLNLTFRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 280389 seqs, 12964817 residues

Total number of hits satisfying chosen parameters: 280389

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_AA_New.*

1: /cgn2_6/ptodata/2/paa/PCT_NEW_COMB.pcp.*
2: /cgn2_6/ptodata/2/paa/US05_NEW_COMB.pcp.*
3: /cgn2_6/ptodata/2/paa/US07_NEW_COMB.pcp.*
4: /cgn2_6/ptodata/2/paa/US08_NEW_COMB.pcp.*
5: /cgn2_6/ptodata/2/paa/US09_NEW_COMB.pcp.*
6: /cgn2_6/ptodata/2/paa/US60_NEW_COMB.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB ID	Description
1	334	100.0	2261	1	PCT-US01-04098A-1212	Sequence 1212, Ap
2	334	100.0	2261	5	US-09-526-193A-1	Sequence 1, Appl
3	334	100.0	2263	1	PCT-US01-04098A-3180	Sequence 3180, Ap
4	205	61.4	302	1	PCT-US01-11988-908	Sequence 908, App
5	205	61.4	302	5	US-09-833-245-908	Sequence 908, App
6	117	35.0	21	5	US-09-526-193A-37	Sequence 37, Appl
7	62.5	18.7	774	6	US-60-248-505-1176	Sequence 1176, Ap
8	56.5	16.9	551	1	PCT-US01-04098A-1326	Sequence 1326, Ap
9	56.5	16.9	595	1	PCT-US01-04098A-3294	Sequence 3294, Ap
10	56	16.8	284	1	PCT-US01-01310-71	Sequence 71, Appl
11	56	16.8	378	1	PCT-US01-01310-77	Sequence 77, Appl
12	53	15.9	183	1	PCT-US01-01310-102	Sequence 102, App
13	53	15.9	183	1	PCT-US01-01332-806	Sequence 806, App
14	53	15.9	370	5	US-09-383-745-1	Sequence 1, Appl
15	53	15.9	379	1	PCT-US01-01310-79	Sequence 79, Appl
16	53	15.9	586	6	US-60-248-505-1178	Sequence 1178, Ap
17	52	15.6	191	5	US-09-811-284-161	Sequence 161, App
18	52	15.6	695	6	US-60-248-505-696	Sequence 696, App
19	51.5	15.4	333	5	US-09-826-509-509	Sequence 509, App
20	51	15.3	269	5	US-09-383-745-3	Sequence 3, Appl
21	50.5	15.1	446	5	US-09-826-509-487	Sequence 487, App
22	50.5	15.1	1422	4	US-08-467-344A-81	Sequence 81, Appl
23	50	15.0	150	1	PCT-US01-03782A-115	Sequence 115, App
24	50	15.0	366	1	PCT-US01-11988-2066	Sequence 2066, Ap
25	50	15.0	366	5	US-09-781-417-46	Sequence 46, Appl
26	50	15.0	366	5	US-09-833-245-2066	Sequence 2066, Ap
27	49.5	14.8	319	1	PCT-US01-04098A-1067	Sequence 1067, Ap

Sequence 3035, Ap
Sequence 1000, Ap
Sequence 1800, Ap
Sequence 13288, A
Sequence 2968, Ap
Sequence 1411, Ap
Sequence 1413, Ap
Sequence 1411, Ap
Sequence 1413, Ap
Sequence 821, App
Sequence 821, App
Sequence 959, App
Sequence 1412, Ap
Sequence 1412, Ap
Sequence 10498, A
Sequence 1921, Ap
Sequence 2, Appli
Sequence 298, App

ALIGNMENTS

RESULT 1

PCT-US01-04098A-1212
; Sequence 1212, Application PC/TUS0104098A
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-029
; CURRENT APPLICATION NUMBER: PCT/US01/04098A
; CURRENT FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: Not Yet Assigned
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/728,422
; PRIOR FILING DATE: 2000-11-30
; PRIOR APPLICATION NUMBER: 09/693,325
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/663,561
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/654,936
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 09/620,325
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/598,075
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 09/560,875
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 09/496,914
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 3960
; SOFTWARE: Custom
; SEQ ID NO 1212
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-04098A-1212

Query Match 100.0%; Score 334; DB 1; Length 2261;
Best Local Similarity 100.0%; Pred. No. 1.4e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKLNLTFRRTQCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLKLNLTFRRTQCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNKA 60

RESULT 2

US-09-526-193A-1
; Sequence 1, Application US/09526193A
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.


```

Qy      41  SVRLSYPPYEQHECHFPNKA  60
          |||||
Db      2  SVRLSYPPYEQHECHFPNKA  21

RESULT 7
US-60-248-505-1176
; Sequence 1176, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: CL000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15

```

```

RESULT      8
PCT-US01-04098A-1326
; Sequence 1326, Application PC/TUS0104098A
; GENERAL INFORMATION:
; APPLICANT: Hyseq. Inc.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-029
; CURRENT APPLICATION NUMBER: PCT/US01/04098A
; CURRENT FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: Not Yet Assigned
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/728,422
; PRIOR FILING DATE: 2000-11-30
; PRIOR APPLICATION NUMBER: 09/693,325
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/663,561
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/654,936
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 09/620,325
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/598,075
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 09/560,875
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 09/496,914
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 3960
; SOFTWARE: Custom
; SEQ ID NO 1326
; LENGTH: 551
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-04098A-1326

```

```

Query Match      16.9%; Score 56.5; DB 1; Length 551;
Best Local Similarity 31.6%; Pred. No. 59;
Matches 18; Conservative 8; Mismatches 22; Indels 9; Gaps 2;

QY      4  WPQLRLLLWNKLTFRRTQTCOLL-----LEVAVPLF---IFLLISVRLSYPPYEQ 51
      || || || || || | : : ||:| | : : : : || | :
Db      182  WPALRSLLHRLNVLRTHQPARYSLTPEGLAQALAESEGLSLNVGIGKPEPPGEE 238

RESULT      9
PCT-US01-04098A-3294
; Sequence 3294, Application PC/TUS0104098A
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides

```

; FILE REFERENCE: 21272-029
; CURRENT APPLICATION NUMBER: PCT/US01/04098A
; CURRENT FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: Not Yet Assigned
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/728,422
; PRIOR FILING DATE: 2000-11-30
; PRIOR APPLICATION NUMBER: 09/693,325
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/663,561
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/654,936
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 09/620,325
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/598,075
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 09/560,875
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 09/496,914
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 3960
; SOFTWARE: Custom
; SEQ ID NO 3294
; LENGTH: 595
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-04098A-3294

Query Match 16.9%; Score 56.5; DB 1; Length 595;
Best Local Similarity 31.6%; Pred. No. 62;
Matches 18; Conservative 8; Mismatches 22; Indels 9; Gaps 2;
QY 4 WPOLRLLNKLTFRRTQCQLL-----LEVAVPLF-----IFLLISVRLSYPPYEQ 51
Db 226 WPAULSLHRLNLVLRTHOPARYSLTPEGLELAQKLAESGLSLNNGVIGPKPEGEE 282

RESULT 10
PCT-US01-01310-71
; Sequence 71, Application PC/TUS0101310
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc., et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PJ203PCT
; CURRENT APPLICATION NUMBER: PCT/US01/01310
; CURRENT FILING DATE: 2001-05-09
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 71
; LENGTH: 284
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-01310-71

Query Match 16.8%; Score 56; DB 1; Length 284;
Best Local Similarity 24.2%; Pred. No. 41;
Matches 15; Conservative 11; Mismatches 10; Indels 26; Gaps 3;

QY 8 RLLLNKLTFRRTQCQLLLEAVAPLFIIFLLISVRLSYPPY-----EQHECHFP 57
Db 139 RMTLW-----TCAAVICMAWTL-----SVAMAPPVFDVGTXXKFIREDQCIFE 182
QY 58 NK 59
Db 183 HR 184

RESULT 11
PCT-US01-01310-77

; Sequence 77, Application PC/TUS0101310
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc., et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PJ203PCT
; CURRENT APPLICATION NUMBER: PCT/US01/01310
; CURRENT FILING DATE: 2001-05-09
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 77
; LENGTH: 378
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-01310-77

Query Match 16.8%; Score 56; DB 1; Length 378;
Best Local Similarity 24.2%; Pred. No. 50;
Matches 15; Conservative 11; Mismatches 10; Indels 26; Gaps 3;

QY 8 RLLLNKLTFRRTQCQLLLEAVAPLFIIFLLISVRLSYPPY-----EQHECHFP 57
Db 139 RMTLW-----TCAAVICMAWTL-----SVAMAPPVFDVGTXXKFIREDQCIFE 182
QY 58 NK 59
Db 183 HR 184

RESULT 12
PCT-US01-01310-102
; Sequence 102, Application PC/TUS0101310
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc., et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PJ203PCT
; CURRENT APPLICATION NUMBER: PCT/US01/01310
; CURRENT FILING DATE: 2001-05-09
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 102
; LENGTH: 183
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (170)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
PCT-US01-01310-102

Query Match 15.9%; Score 53; DB 1; Length 183;
Best Local Similarity 25.4%; Pred. No. 65;
Matches 15; Conservative 9; Mismatches 9; Indels 26; Gaps 3;

QY 8 RLLLNKLTFRRTQCQLLLEAVAPLFIIFLLISVRLSYPPY-----EQHECHFP 56
Db 139 RMTLW-----TCAAVICMAWTL-----SVAMAPPVFDVGTXXKFIREDKCIF 181

RESULT 13
PCT-US01-01332-806
; Sequence 806, Application PC/TUS0101332
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc., et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PJ202PCT
; CURRENT APPLICATION NUMBER: PCT/US01/01332
; CURRENT FILING DATE: 2001-05-09
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1249

QY 13 KNLTFRRROTQCLLEAVAMPFLFLLISVRLSYPPY-----EQHECHFPNKA 60
| | | | | : : : : : | : : : : :
Db 140 KRLTF---WTCLAVICMWTL-----SVAMAFPPVLDVGTYSFIREEDQCTFQHRS 187

Search completed: May 31, 2001, 13:08:13
Job time: 294 sec

SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 806
LENGTH: 183
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (170)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
PCT-US01-01332-806

Query Match 15.9%; Score 53; DB 1; Length 183;
Best Local Similarity 25.4%; Pred. No. 65;
Matches 15; Conservative 9; Mismatches 9; Indels 26; Gaps 3;
QY 8 RLLWKNLTFRRROTQCLLEAVAMPFLFLLISVRLSYPPY-----EQHECHFPNKA 56
| | | | | : : : : : | : : : : :
Db 139 RMTLW-----TCAAVICMWTL-----SVAMAFPPVLDVGTYSFIREEDQCTFQHRS 181

RESULT 14
US-09-383-745-1
Sequence 1, Application US/09383745
GENERAL INFORMATION:
APPLICANT: Gluckmann, Maria A.
TITLE OF INVENTION: 14926 Receptor, A Novel G-Protein Coupled Receptor
FILE REFERENCE: 035800/169197
CURRENT APPLICATION NUMBER: US/09/383,745
CURRENT FILING DATE: 1999-08-26
PRIOR APPLICATION NUMBER: 09/145,745
PRIOR FILING DATE: 1998-09-02
NUMBER OF SEQ ID NOS: 3
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 370
TYPE: PRT
ORGANISM: Homo sapiens
US-09-383-745-1

Query Match 15.9%; Score 53; DB 5; Length 370;
Best Local Similarity 25.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 11; Mismatches 12; Indels 20; Gaps 3;
QY 13 KNLTFRRROTQCLLEAVAMPFLFLLISVRLSYPPY-----EQHECHFPNKA 60
| | | | | : : : : : | : : : : :
Db 131 KRLTF---WTCLAVICMWTL-----SVAMAFPPVLDVGTYSFIREEDQCTFQHRS 178

RESULT 15
PCT-US01-01310-79
Sequence 79, Application PC/TUS0101310
GENERAL INFORMATION:
APPLICANT: Human Genome Sciences, Inc., et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: FJ203PCT
CURRENT APPLICATION NUMBER: PCT/US01/01310
CURRENT FILING DATE: 2001-05-09
Prior application data removed - refer to PALM or file wrapper
NUMBER OF SEQ ID NOS: 116
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 79
LENGTH: 379
TYPE: PRT
ORGANISM: Homo sapiens
PCT-US01-01310-79

Query Match 15.9%; Score 53; DB 1; Length 379;
Best Local Similarity 25.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 11; Mismatches 12; Indels 20; Gaps 3;

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:20:09 ; Search time 92.94 seconds
(without alignments)
103.844 Million cell updates/sec

Title: US-09-526-193A-1_COPY_1_60
Perfect score: 334
Sequence: 1 MACWPQLRLLLWNLTFRRR.....SVRLSPYPYEQHECHFPNKA 60

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1009251 seqs, 160854530 residues

Total number of hits satisfying chosen parameters: 1009251

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_AA_Main:*

1: /cgn2_6/ptodata/1/paa/PCTUS_COMB.pep.*
2: /cgn2_6/ptodata/1/paa/US06_COMB.pep.*
3: /cgn2_6/ptodata/1/paa/US07_COMB.pep.*
4: /cgn2_6/ptodata/1/paa/US080_COMB.pep.*
5: /cgn2_6/ptodata/1/paa/US081_COMB.pep.*
6: /cgn2_6/ptodata/1/paa/US082_COMB.pep.*
7: /cgn2_6/ptodata/1/paa/US083_COMB.pep.*
8: /cgn2_6/ptodata/1/paa/US084_COMB.pep.*
9: /cgn2_6/ptodata/1/paa/US085_COMB.pep.*
10: /cgn2_6/ptodata/1/paa/US086_COMB.pep.*
11: /cgn2_6/ptodata/1/paa/US087_COMB.pep.*
12: /cgn2_6/ptodata/1/paa/US088_COMB.pep.*
13: /cgn2_6/ptodata/1/paa/US089_COMB.pep.*
14: /cgn2_6/ptodata/1/paa/US090_COMB.pep.*
15: /cgn2_6/ptodata/1/paa/US091_COMB.pep.*
16: /cgn2_6/ptodata/1/paa/US092_COMB.pep.*
17: /cgn2_6/ptodata/1/paa/US093_COMB.pep.*
18: /cgn2_6/ptodata/1/paa/US094_COMB.pep.*
19: /cgn2_6/ptodata/1/paa/US095_COMB.pep.*
20: /cgn2_6/ptodata/1/paa/US096_COMB.pep.*
21: /cgn2_6/ptodata/1/paa/US097_COMB.pep.*
22: /cgn2_6/ptodata/1/paa/US098_COMB.pep.*
23: /cgn2_6/ptodata/1/paa/US60_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	334	100.0	162	23	US-60-169-629-486
2	334	100.0	162	23	US-60-187-470-486
3	334	100.0	2261	1	PCT-US00-06745-1
4	334	100.0	2261	19	US-09-526-193-1
5	334	100.0	2261	20	US-09-654-323-5
6	230	68.9	101	23	US-60-206-111-183
7	230	68.9	145	1	PCT-US00-30628A-175
8	230	68.9	2083	23	US-60-230-445-1448
9	230	68.9	2180	23	US-60-221-839-5
10	230	68.9	2180	23	US-60-230-445-2002

11	205	61.4	302	1	PCT-US00-30628A-101	Sequence 101, App
12	180	53.9	145	1	PCT-US00-30628A-178	Sequence 178, App
13	180	53.9	1446	23	US-60-258-275-311	Sequence 311, App
14	180	53.9	2235	14	US-09-032-438-6	Sequence 6, Appli
15	180	53.9	2273	14	US-09-032-438-3	Sequence 3, Appli
16	120	35.9	1875	23	US-60-230-445-1535	Sequence 1535, Ap
17	117	35.0	21	1	PCT-US00-06745-37	Sequence 37, Appl
18	117	35.0	21	19	US-09-526-193-37	Sequence 37, Appl
19	104	31.1	210	23	US-60-213-846-938	Sequence 938, App
20	104	31.1	2436	21	US-09-795-693-8	Sequence 8, Appli
21	104	31.1	2436	23	US-60-232-685-2	Sequence 2, Appli
22	103	30.8	2436	1	PCT-US00-40789-2	Sequence 2, Appli
23	86	25.7	1704	11	US-08-720-614-75	Sequence 75, Appl
24	86	25.7	2319	23	US-60-207-583-427	Sequence 427, App
25	86	25.7	2431	23	US-60-230-445-1964	Sequence 1964, Ap
26	86	25.7	3040	23	US-60-230-445-1210	Sequence 1210, Ap
27	78	23.4	1713	23	US-60-171-625-45	Sequence 45, Appl
28	78	23.4	1713	23	US-60-173-464-1728	Sequence 1728, Ap
29	78	23.4	1713	23	US-60-191-637-2064	Sequence 2064, Ap
30	78	23.4	1713	23	US-60-191-681-1647	Sequence 1647, Ap
31	78	23.4	1713	23	US-60-219-005-18	Sequence 18, Appl
32	70	21.0	100	23	US-60-147-499-4269	Sequence 4269, Ap
33	70	21.0	101	23	US-60-197-873-17098	Sequence 17098, A
34	70	21.0	1642	23	US-60-223-269-3	Sequence 3, Appli
35	63	18.9	63	1	PCT-US01-01354-13508	Sequence 13508, A
36	62.5	18.7	426	23	US-60-207-583-607	Sequence 607, App
37	62.5	18.7	426	23	US-60-230-445-1682	Sequence 1682, Ap
38	61.5	18.4	2271	23	US-60-173-464-27974	Sequence 27974, A
39	61.5	18.4	2272	23	US-60-191-637-36418	Sequence 36418, A
40	61.5	18.4	2272	23	US-60-191-681-28456	Sequence 28456, A
41	61	18.3	218	23	US-60-161-932-2601	Sequence 2601, Ap
42	60.5	18.1	464	18	US-09-450-969-4444	Sequence 4444, Ap
43	60.5	18.1	529	18	US-09-413-198-2403	Sequence 2403, Ap
44	59.5	17.8	181	18	US-09-417-507-38344	Sequence 38344, A
45	59.5	17.8	224	1	PCT-US93-09987-10	Sequence 10, Appl

ALIGNMENTS

RESULT 1
US-60-169-629-486
; Sequence 486, Application US/60169629
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Bougueleret, L.
; TITLE OF INVENTION: CDNAS for Secreted Proteins
; FILE REFERENCE: GENSET.071PRF
; CURRENT APPLICATION NUMBER: US/60/169, 629
; CURRENT FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 715
; SOFTWARE: Patent.pm
; SEQ ID NO 486
; LENGTH: 162
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -47..-1
US-60-169-629-486

Query Match	100.0%	Score 334;	DB 23;	Length 162;
Best Local Similarity	100.0%;	Pred. No. 2.8e-31;		
Matches	60;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0;
QY	1	MACWPQLRLLLWNLTFRRRQTCOLLEVAWPLFI	FI	LI
DB	1	MACWPQLRLLLWNLTFRRRQTCOLLEVAWPLFI	FI	LI
RESULT	2			

```
US-60-187-470-486
; Sequence 486, Application US/60187470
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Bouqueloret, L.
; APPLICANT: Jobert, S.
; TITLE OF INVENTION: cDNAs for Secreted Proteins
; FILE REFERENCE: 78.US2.PRO
; CURRENT APPLICATION NUMBER: US/60/187,470
; CURRENT FILING DATE: 2000-03-06
; NUMBER OF SEQ ID NOS: 715
; SOFTWARE: Patent.pm
; SEQ ID NO 486
; LENGTH: 162
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: SIGNAL
; LOCATION: -47...-1
US-60-187-470-486

Query Match          100.0%; Score 334; DB 23; Length 162;
Best Local Similarity 100.0%; Pred. No. 2.8e-31;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||

RESULT 3
PCT-US00-06745-1
; Sequence 1, Application PC/TUS0006745
; GENERAL INFORMATION:
; APPLICANT: University of British Columbia
; APPLICANT: Xenon Bioresearch, Inc.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING
; TITLE OF INVENTION: CHOLESTEROL LEVELS
; FILE REFERENCE: 50110/002W05
; CURRENT APPLICATION NUMBER: PCT/US00/06745
; CURRENT FILING DATE: 2000-04-15
; PRIOR APPLICATION NUMBER: 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: 60/151,977
; PRIOR FILING DATE: 1999-09-01
; NUMBER OF SEQ ID NOS: 287
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US00-06745-1

Query Match          100.0%; Score 334; DB 1; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.6e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||

RESULT 4
US-09-526-193-1
; Sequence 1, Application US/09526193
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
```

```
; APPLICANT: Wilson, Angela R.
; APPLICANT: Pimstone, Simon N.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING
; TITLE OF INVENTION: CHOLESTEROL LEVELS
; FILE REFERENCE: 50110/002005
; CURRENT APPLICATION NUMBER: US/09/526,193
; CURRENT FILING DATE: 2000-03-15
; EARLIER APPLICATION NUMBER: 60/124,702
; EARLIER FILING DATE: 1999-03-15
; EARLIER APPLICATION NUMBER: 60/138,048
; EARLIER FILING DATE: 1999-06-08
; EARLIER APPLICATION NUMBER: 60/139,600
; EARLIER FILING DATE: 1999-06-17
; EARLIER APPLICATION NUMBER: 60/151,977
; EARLIER FILING DATE: 1999-09-01
; NUMBER OF SEQ ID NOS: 287
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-526-193-1
```

```
Query Match          100.0%; Score 334; DB 19; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.6e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||
```

```
RESULT 5
US-09-654-323-5
; Sequence 5, Application US/09654323
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 50110/004002
; CURRENT APPLICATION NUMBER: US/09/654,323
; CURRENT FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: homo sapien
US-09-654-323-5
```

```
Query Match          100.0%; Score 334; DB 20; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.6e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 MACWPQLRLLLNKLTFRRTQTCOLLLEAVWPLFLFILISVRLSYPPYEQHECHFPNKA 60
|||||
```

```

; CURRENT FILING DATE: 2000-09-06
; NUMBER OF SEQ ID NOS: 3051
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1448
; LENGTH: 2083
; TYPE: PRT
; ORGANISM: HUMAN
US-60-230-445-1448

Query Match      68.9%      Score 230:  DB 23:  Length 2083;
Best Local Similarity 67.8%;  Pred. No. 3.5e-18;
Matches 40:  Conservative 7;  Mismatches 12;  Indels 0;  Gaps 0;

Oy 1 MACPQRLLLKWLNTERRRQTCLLLEAVMPLEFLLILISVRLSYPPYEQHECHFPNK 59
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 1 MAFWTQLMLLLKKNFMYRRRPVQLLVELLWPLFLFFILVAVRSHSHPPLEHHECHFPNK 59
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 9
US-60-221-839-5
; Sequence 5, Application US/60221839
; GENERAL INFORMATION:
; APPLICANT: Yue, Henry
; APPLICANT: Lal, Preeti
; APPLICANT: Yue, Henry
; APPLICANT: Walia, Narinder K.
; APPLICANT: Baughn, Mariah R.
; APPLICANT: Triboulevy, Catherine M.
; APPLICANT: Yang, Junming
; APPLICANT: Thornton, Michael
; APPLICANT: Hafalia, April
; APPLICANT: Patterson, Chandra
; APPLICANT: Greene, Barrie D.
; APPLICANT: Yao, Monique G.
; APPLICANT: Raumann, Brigitte E.
; APPLICANT: Gandhi, Aneena R.
; APPLICANT: Lu, Yan
; APPLICANT: Ding, Li
; APPLICANT: Tang, Y.Tom
; APPLICANT: Azimzai, Valda
; APPLICANT: Burford, Neil
; APPLICANT: Sellhamer, Jeffrey J.
; APPLICANT: Borowsky, Mark L.
; APPLICANT: Nguyen, Dannel B.
; APPLICANT: Khan, Farrah A.
; APPLICANT: Elliott, Vicki S.
; APPLICANT: Kearney, Liam
; APPLICANT: Lu, Dyung Aina M.
; APPLICANT: Thangavelu, Kavitha
; APPLICANT: Xu, Yuming
; APPLICANT: Sanjanwala, Madhu Sudan
; APPLICANT: Das, Debopriya
; APPLICANT: Policky, Jennifer L.
; TITLE OF INVENTION: TRANSPORTERS AND ION CHANNELS
; FILE REFERENCE: PI-0170 P
; CURRENT APPLICATION NUMBER: US/60/221.839
; CURRENT FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PERL Program
; SEQ ID NO 5:
; LENGTH: 2180
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 7475603CD1
US-60-221-839-5

Query Match      68.9%      Score 230:  DB 23:  Length 2180;
Best Local Similarity 67.8%;  Pred. No. 3.6e-18;
Matches 40:  Conservative 7;  Mismatches 12;  Indels 0;  Gaps 0;

```

```

QY 1 MACHPQLRLLLKKNLTFRRRTCTCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNK 59
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 35 MAFTQLMLLLKKNFYRRRQPVQLLVLLPFLFFILVAVRSHPPLEHHECHFPNK 93

RESULT 10
PCT-US00-230-445-2002
; Sequence 2002, Application US/60230445
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN TRANSPORTER PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS,
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: CL000765
; CURRENT APPLICATION NUMBER: US/60/230,445
; CURRENT FILING DATE: 2000-09-06
; NUMBER OF SEQ ID NOS: 3051
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2002
; LENGTH: 2180
; TYPE: PRT
; ORGANISM: HUMAN
US-60-230-445-2002

Query Match 68.9%; Score 230; DB 23; Length 2180;
Best Local Similarity 67.8%; Pred. No. 3.6e-18;
Matches 40; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

QY 1 MACHPQLRLLLKKNLTFRRRTCTCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNK 59
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 MAFTQLMLLLKKNFYRRRQPVQLLVLLPFLFFILVAVRSHPPLEHHECHFPNK 59

RESULT 11
PCT-US00-30628A-101
; Sequence 101, Application PC/TUS0030628A
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc.
; TITLE OF INVENTION: 28 Human Secreted Proteins
; FILE REFERENCE: PS712PCT
; CURRENT APPLICATION NUMBER: PCT/US00/30628A
; CURRENT FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/164,744
; PRIOR FILING DATE: 1999-11-12
; PRIOR APPLICATION NUMBER: 60/215,140
; PRIOR FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 190
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 101
; LENGTH: 302
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (262)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (279)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (294)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (295)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
PCT-US00-30628A-101

Query Match 61.4%; Score 205; DB 1; Length 302;
Best Local Similarity 68.6%; Pred. No. 5.5e-16;
Matches 35; Conservative 7; Mismatches 9; Indels 0; Gaps 0;

```

```

QY 9 LLLWKNLTFRRRTCTCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNK 59
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2 LLLWKNFYRRRQPVQLLVLLPFLFFILVAVRSHPPLEHHECHFPNK 52

RESULT 12
PCT-US00-30628A-178
; Sequence 178, Application PC/TUS0030628A
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc.
; TITLE OF INVENTION: 28 Human Secreted Proteins
; FILE REFERENCE: PS712PCT
; CURRENT APPLICATION NUMBER: PCT/US00/30628A
; CURRENT FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/164,744
; PRIOR FILING DATE: 1999-11-12
; PRIOR APPLICATION NUMBER: 60/215,140
; PRIOR FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 190
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 178
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US00-30628A-178

Query Match 53.9%; Score 180; DB 1; Length 145;
Best Local Similarity 56.4%; Pred. No. 2.5e-13;
Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 6 QLRLLWKNLTFRRRTCTCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNK 60
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 6 QIQLLWKNLTKRKQIRFVVELVWPLSLFLVLIWRNANPLYSHHECHFPNK 60

RESULT 13
US-60-258-275-311
; Sequence 311, Application US/60258275
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN TRANSPORTER PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS,
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: CL001026-PROV
; CURRENT APPLICATION NUMBER: US/60/258,275
; CURRENT FILING DATE: 2000-12-27
; NUMBER OF SEQ ID NOS: 717
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 311
; LENGTH: 1446
; TYPE: PRT
; ORGANISM: HUMAN
US-60-258-275-311

Query Match 53.9%; Score 180; DB 23; Length 1446;
Best Local Similarity 56.4%; Pred. No. 1.8e-12;
Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 6 QLRLLWKNLTFRRRTCTCLLLEAVAMPFLIFILISVRLSYPPYEQHECHFPNK 60
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 32 QIQLLWKNLTKRKQIRFVVELVWPLSLFLVLIWRNANPLYSHHECHFPNK 86

RESULT 14
US-09-032-438-6
; Sequence 6, Application US/09032438
; GENERAL INFORMATION:
; APPLICANT: Allikmets, Rando, Anderson, Kent L., Dean, Michael, Leppert,
; APPLICANT: Mark, Lewis, Richard A., Li, Yixin, Lupsaki, James R., Nathans, Jerem
; APPLICANT: Amir, Shroyer, Noah F., Singh, Nanda, Smallwood, Phillip, M., Sun, Hu
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES

```

Search completed: May 31, 2001, 13:07:08
Job time: 2819 sec

RESULT 15
US-09-032-438-3
: Sequence 3, Application US/09032438
: GENERAL INFORMATION:
: APPLICANT: Allikmets, Rando, Anderson, Kent L., Dean, Michael, Leppert,
: APPLICANT: Mark, Lewis, Richard A., Li, Yixin, Lupski, James R., Nathans, Jeremy,
: APPLICANT: Amir, Shroyer, Noah F., Singh, Nanda, Smallwood, Philip, M., Sun, Hui
: TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
: TITLE OF INVENTION: FOR ATP-BINDING CASSETTE TRANSPORTER AND METHODS OF
: TITLE OF INVENTION: SCREENING FOR AGENTS THAT MODIFY ATP-BINDING CASSETTE
: TITLE OF INVENTION: TRANSPORTER
: NUMBER OF SEQUENCES: 117
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris
: ADDRESSEE: LLP
: STREET: One Liberty Place - 46th Floor
: CITY: Philadelphia
: STATE: PA
: COUNTRY: USA
: ZIP: 19103
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:18:09 ; Search time 25.08 seconds
(without alignments)
45.959 Million cell updates/sec

Title: US-09-526-193a-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLNKLTFR...SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 185757 seqs, 19210857 residues

Total number of hits satisfying chosen parameters: 185757

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents_AA:*

- 1: /cgn2_6/ptodata/1/1aa/5A_COMB.pep.*
- 2: /cgn2_6/ptodata/1/1aa/5B_COMB.pep.*
- 3: /cgn2_6/ptodata/1/1aa/6A_COMB.pep.*
- 4: /cgn2_6/ptodata/1/1aa/6B_COMB.pep.*
- 5: /cgn2_6/ptodata/1/1aa/PTUS_COMB.pep.*
- 6: /cgn2_6/ptodata/1/1aa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	DB ID	Description
1	86	25.7	1704	3	US-08-762-500-75
2	58.5	17.5	382	3	US-08-811-177A-2
3	58	17.4	382	2	US-08-872-302-2
4	56.5	16.9	1969	4	US-08-836-325-16
5	56	16.8	921	1	US-07-872-644-39
6	56	16.8	921	1	US-08-297-494-39
7	56	16.8	921	1	US-08-297-510-39
8	56	16.8	921	1	US-08-479-532-39
9	56	16.8	921	1	US-08-455-526-39
10	56	16.8	921	1	US-08-455-525-39
11	56	16.8	921	3	US-09-139-491-39
12	56	16.8	921	5	PCT-US92-03222-39
13	56	16.8	941	1	US-07-872-644-45
14	56	16.8	941	1	US-08-297-494-45
15	56	16.8	941	1	US-08-297-510-45
16	56	16.8	941	1	US-08-479-532-45
17	56	16.8	941	1	US-08-455-526-45
18	56	16.8	941	1	US-08-455-525-45
19	56	16.8	941	5	US-09-139-491-45
20	56	16.8	941	5	PCT-US92-03222-45
21	56	16.8	942	1	US-07-872-644-43
22	56	16.8	942	1	US-08-297-494-43
23	56	16.8	942	1	US-08-297-510-43
24	56	16.8	942	1	US-08-479-532-43
25	56	16.8	942	1	US-08-455-526-43
26	56	16.8	942	1	US-08-455-525-43
27	56	16.8	942	3	US-09-139-491-43

28	56	16.8	942	5	PCT-US92-03222-43
29	56	16.8	1375	3	US-08-665-259-26
30	56	16.8	1375	3	US-08-762-500-26
31	55	16.5	232	3	US-09-024-020B-6
32	55	16.5	383	1	US-08-314-596-41
33	55	16.5	383	1	US-08-320-982-41
34	55	16.5	383	3	US-08-819-037-41
35	55	16.5	1976	3	US-09-024-020B-9
36	55	16.5	1978	3	US-09-024-020B-3
37	55	16.5	1988	3	US-09-024-020B-4
38	54.5	16.3	1011	4	US-08-836-325-2
39	54.5	16.3	1984	4	US-08-836-325-10
40	54.5	16.3	1989	4	US-08-836-325-12
41	53	15.9	370	3	US-09-251-373-2
42	53	15.9	2005	4	US-08-836-325-7
43	52.5	15.7	387	1	US-08-314-596-40
44	52.5	15.7	387	1	US-08-314-596-42
45	52.5	15.7	387	1	US-08-320-982-40

ALIGNMENTS

RESULT 1
US-08-762-500-75
; Sequence 75, Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Rady, Terence J.
; APPLICANT: Klingner, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; TITLE OF INVENTION: COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/762,500
FILING DATE: 09-DEC-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/665,259
FILING DATE: 17-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/10469
FILING DATE: 17-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IG5-9.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (508) 872-8400
TELEFAX: (508) 872-5415
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 1704 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-762-500-75

Sequence 43, Appl
Sequence 26, Appl
Sequence 26, Appl
Sequence 6, Appl
Sequence 41, Appl
Sequence 41, Appl
Sequence 9, Appl
Sequence 2, Appl
Sequence 4, Appl
Sequence 4, Appl
Sequence 2, Appl
Sequence 10, Appl
Sequence 12, Appl
Sequence 2, Appl
Sequence 7, Appl
Sequence 40, Appl
Sequence 42, Appl
Sequence 40, Appl

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;


```

: APPLICATION NUMBER: 08/297,494
: FILING DATE:
: APPLICATION NUMBER: US 07/688,356
: FILING DATE: 04-APR-1991
: ATTORNEY/AGENT INFORMATION:
: NAME: NO. 5800987and, Greta E.
: REGISTRATION NUMBER: 35,302
: REFERENCE/DOCKET NUMBER: 27866/30822
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (312) 346-5750
: TELEFAX: (312) 984-9740
: TELEX: 25-3856
: INFORMATION FOR SEQ ID NO: 39:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 921 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
: US-08-455-525-39

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels

QY 3 CWPQLRLLLKWLKLTFRRR---TCOLLELVAMPFLFLLISVRL 44
: : : : : : : : : : : : : : : : : : : : : : : : :
: : : : : : : : : : : : : : : : : : : : : : : : :
Db 349 CFHTSTVLTSTLAFQKEQKLKCEQALQVAKNLFTHLDDVSVLL 394
: : : : : : : : : : : : : : : : : : : : : : : : :
: : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 11
US-09-139-491-39
: Sequence 39 Application US/09139491
: Patent No. 6015877
: GENERAL INFORMATION:
: APPLICANT: Beavo, Joseph A.
: APPLICANT: Bentley, Kelley
: APPLICANT: Charbonneau, Harry
: APPLICANT: Sonnenburg, William K.
: TITLE OF INVENTION: DNA Encoding Mammalian
: TITLE OF INVENTION: Phosphodiesterases
: NUMBER OF SEQUENCES: 58
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
: ADDRESSEE: Bicknell
: STREET: Two First National Plaza, 20 South Clark
: STREET: Street
: CITY: Chicago
: STATE: Illinois
: COUNTRY: USA
: ZIP: 60603
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/139,491
: FILING DATE:
: CLASSIFICATION:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US/08/455,525
: FILING DATE: 31-MAY-1995
: APPLICATION NUMBER: 08/297,494
: FILING DATE:
: APPLICATION NUMBER: US 07/688,356
: FILING DATE: 04-APR-1991
: ATTORNEY/AGENT INFORMATION:
: NAME: NO. 6015677and, Greta E.
: REGISTRATION NUMBER: 35,302
: REFERENCE/DOCKET NUMBER: 27866/30822
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (312) 346-5750

```

Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels

APPLICANT: BENLEY, KELLEY
APPLICANT: Charbonneau, Harry

```

RESULT 15
US-08-297-410-45
; Sequence 45, Application US/08297510
; Patent No. 5602019
; GENERAL INFORMATION:
; APPLICANT: Beavo, Joseph A.
; APPLICANT: Bentley, Kelley
; APPLICANT: Charbonneau, Harry
; APPLICANT: Sonnenburg, William K.
; TITLE OF INVENTION: DNA Encoding Mammalian
; TITLE OF INVENTION: Phosphodiesterases
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

Search completed: May 31, 2001, 13:04:32
Job time: 2783 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:15:29 ; Search time 46.78 Seconds
(without alignments)
73.318 Million cell updates/sec

Title: US-09-526-193A-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKLNKLTFRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues

Total number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_0401.*
1: /SID56/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SID56/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SID56/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SID56/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SID56/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SID56/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SID56/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SID56/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SID56/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SID56/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SID56/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SID56/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SID56/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SID56/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SID56/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SID56/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SID56/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SID56/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SID56/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SID56/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SID56/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SID56/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	334	100.0	2143	21 B38108	Human ABC1 cholest
2	334	100.0	2259	21 B38107	Human ABC1 FHA-3 m
3	334	100.0	2260	21 B38106	Human ABC1 cholest
4	334	100.0	2261	21 B38082	Human ABC1 cholest
5	334	100.0	2261	21 B38104	Human ABC1 cholest
6	334	100.0	2261	21 B38105	Human ABC1 cholest
7	334	100.0	2261	21 B38109	Human ABC1 cholest
8	334	100.0	2261	21 B38110	Human ABC1 cholest
9	334	100.0	2261	21 B38111	Human ABC1 cholest
10	334	100.0	2261	21 B38112	Human ABC1 cholest
11	334	100.0	2261	21 B38113	Human ABC1 cholest

12	334	100.0	2261	21 B38114	Human ABC1 cholest
13	334	100.0	2261	21 B38115	Human ABC1 cholest
14	334	100.0	2261	21 B38116	Human ABC1 cholest
15	334	100.0	2261	21 B38117	Human ABC1 cholest
16	230	68.9	112	21 B41102	Human ORFX ORF866
17	180	53.9	2273	19 W70398	ATP binding casset
18	117	35.0	21	21 B38083	Human ABC1 antigen
19	86	25.7	1704	19 W46771	Amino acid sequenc
20	60.5	18.1	502	20 Y49625	Corn hexose carrie
21	59.5	17.8	224	15 R53701	Sequence of castor
22	58.5	17.5	382	18 W31740	Delta-12 desaturas
23	58.5	17.5	4473	17 R97244	Virulence gene clu
24	58	17.4	382	20 W83353	Vernonia galamenen
25	57.5	17.2	255	21 Y70405	Class 1 fatty acid
26	56.5	16.9	272	21 Y83086	F-box protein FBP-
27	56.5	16.9	1387	21 Y95441	Caenorhabditis ele
28	56.5	16.9	1977	17 R95641	Peripheral nervous
29	56	16.8	373	20 Y30534	A G protein-couple
30	56	16.8	373	20 Y30538	A G protein-couple
31	56	16.8	373	21 Y71300	Human orphan G pro
32	56	16.8	373	21 B02834	Human 7TM receptor
33	56	16.8	373	21 Y32237	Human G protein co
34	56	16.8	610	20 Y35481	Chlamydia pneumoni
35	56	16.8	921	16 R69727	Cyclic-GMP stimula
36	56	16.8	921	18 W18048	Cyclic-GMP-stimula
37	56	16.8	921	18 W11252	Clone p3CGS-5 cycl
38	56	16.8	921	19 W71224	CGS-PDE encoded by
39	56	16.8	921	19 W77040	Adrenal cortex Ca2
40	56	16.8	921	19 W60752	CGS-PDE isolated f
41	56	16.8	921	21 Y80984	Bovine adrenal cor
42	56	16.8	941	13 R28409	Human foetal CGS P
43	56	16.8	941	16 R69729	Cyclic-GMP stimula
44	56	16.8	941	18 W18050	Human CGS-PDE amin
45	56	16.8	941	18 W11253	phc9s6n cyclic GMP

ALIGNMENTS

RESULT 1

B38108	ID	B38108 standard; Protein; 2143 AA.
XX	AC	B38108;
XX	AC	B38108;
XX	DT	29-JAN-2001 (first entry)
XX	DT	Human ABC1 cholesterol transporter FHA-1 mutant protein (R21445STOP).
XX	DE	Human ABC1 cholesterol transporter; chromosome 9q31;
XX	KW	ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
XX	KW	Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
XX	KW	cardiovascular disease; coronary artery disease; coronary restenosis;
XX	KW	cerebrovascular disease; peripheral vascular disease;
XX	KW	Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
XX	KW	X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
XX	KW	prognosis; prophylaxis; drug screening; transgenic animal; mutant;
XX	KW	muteln.
XX	OS	Homo sapiens.
XX	PN	WO200055318-A2.
XX	PD	21-SEP-2000.
XX	PF	15-MAR-2000; 2000WO-IB00532.
XX	XX	
PR	15-MAR-1999;	99US-0124702.
PR	08-JUN-1999;	99US-0138048.
PR	17-JUN-1999;	99US-0139600.
PR	01-SEP-1999;	99US-0151977.
XX	XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.	

CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 SQ Sequence 2259 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2259;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWKNLTFRRQTCQLLELVAVPLFIFLLISVRLSYPPYEQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqlrlllwknltfrrrqtcqllelvavplfifllisvrlsyppyeqhechfpnka 60
 RESULT 3
 B38106
 ID B38106 standard; Protein; 2260 AA.
 XX
 AC B38106;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter PHA-1 mutant protein (delta-L693).
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW muten.
 XX
 OS Homo sapiens.
 XX
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 PI Hayden MR., Willson AR, Pimstone SN;
 XX
 DR WPI: 2000-587528/55.
 DR N-PSDB: C69387.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while

CC PHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 SQ Sequence 2260 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2260;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWKNLTFRRQTCQLLELVAVPLFIFLLISVRLSYPPYEQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqlrlllwknltfrrrqtcqllelvavplfifllisvrlsyppyeqhechfpnka 60
 RESULT 4
 B38082
 ID B38082 standard; Protein; 2261 AA.
 XX
 AC B38082;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter.
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal.
 XX
 OS Homo sapiens.
 XX
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX

PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX (XENO-) XENON BIORESEARCH INC.
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI: 2000-587528/55.
 DR N-PSDB; C69120.
 DR
 XX
 XX
 PT New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX
 PS Claim 5; Page 152-157; 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents the human ABC1 cholesterol transporter.
 XX
 SQ Sequence 2261 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWQPLRLLLWKNLFRFRRTQCLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60
 DQ 1 macwqplrlllwnlfrfrtqclllewawpifililsvrlsyppyeqhechfpnka 60
 RESULT 5
 ID B38104
 XX B38104 standard; Protein; 2261 AA.
 AC B38104;
 XX
 XX 29-JAN-2001 (first entry)
 DT
 XX Human ABC1 cholesterol transporter TD-1 mutant protein (C1477R).
 DE
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 CC

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 XX muten.
 OS Homo sapiens.
 XX OS
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 XX 15-MAR-2000; 2000WO-IB00532.
 PF
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PA
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI: 2000-587528/55.
 DR N-PSDB; C69385.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX
 PS Examples; Page : 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

```

XX Sequence 2261 AA;
SQ
Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLKNTFRRTQCQLLEVAWPLFIILLISVRLSYPPYEQHECHFPNKA 60
DB 1 macwpqlrlllwnltfrrrtcqllleavwplfifilllsvrlsyppyeqhechfpnka 60

RESULT 6
B38105
ID B38105 standard; Protein: 2261 AA.
AC B38105;
DT 29-JAN-2001 (first entry)
DE Human ABC1 cholesterol transporter TD-2 mutant protein (Q597R).
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
OS Homo sapiens.
XX
XX WO200055318-A2.
XX 21-SEP-2000.
XX
XX 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
XX 08-JUN-1999; 99US-0138048.
XX 17-JUN-1999; 99US-0139600.
XX 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (XENO-) XENON BIORESEARCH INC.
XX
XX Hayden MR, Wilson AR, Pinstone SN;
XX WPI; 2000-587528/55.
XX N-PSDB; C69386.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
XX ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX disease and cancer -
XX
XX Examples: Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
XX (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
XX a member of the ATP-binding cassette (ABC transporter) superfamily of
XX proteins, and plays a crucial role in cholesterol transport, particularly
XX intracellular cholesterol trafficking in monocytes and fibroblasts, being
XX involved in cholesterol efflux from the cell. The gene encoding ABC1 is
XX located on chromosome 9q31, and mutations in this gene are associated
XX with two genetic HDL (high density lipoprotein) deficiency disorders,
XX Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
XX are distinguishable in that TD is an autosomal recessive disorder, while
XX FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
XX cholesterol") in the blood correlate with a high risk of cardiovascular
XX disease, particularly coronary artery disease, but also cerebrovascular

```

```

CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
XX Sequence 2261 AA;
SQ
Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 MACWPQLRLLLKNTFRRTQCQLLEVAWPLFIILLISVRLSYPPYEQHECHFPNKA 60
DB 1 macwpqlrlllwnltfrrrtcqllleavwplfifilllsvrlsyppyeqhechfpnka 60

```

RESULT 7

B38109
ID B38109 standard; Protein: 2261 AA.

AC B38109;

DT 29-JAN-2001 (first entry)

DE Human ABC1 cholesterol transporter mutant, R219K.

DE Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.

OS Homo sapiens.

PN WO200055318-A2.

XX 21-SEP-2000.

XX 15-MAR-2000; 2000WO-IB00532.

XX 15-MAR-1999; 99US-0124702.

XX 08-JUN-1999; 99US-0138048.

XX 17-JUN-1999; 99US-0139600.

XX 01-SEP-1999; 99US-0151977.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX (XENO-) XENON BIORESEARCH INC.

XX Hayden MR, Wilson AR, Pimstone SN;
 PI WPI: 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. NO. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLILWKLTFRRRTCTCLLEVAWPLFLILISVRLSYPPYQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqlrlilwklntfrfrrtctclllewawplfllilsvrlsyppdqhechfpnka 60

RESULT 8

B38110

ID B38110 standard; Protein; 2261 AA.

XX AC B38110;

XX

29-JAN-2001 (first entry)

XX

Human ABC1 cholesterol transporter mutant, V399A.

DE

Human ABC1 cholesterol transporter; chromosome 9q31;

XX

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; Niemann-Pick disease;
 KW Alzheimer's disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW muteln.
 XX
 OS Homo sapiens.
 XX
 XX WO2000055318-A2.
 PN
 XX 21-SEP-2000.
 PD
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PA
 XX Hayden MR, Wilson AR, Pimstone SN;
 PI
 XX WPI: 2000-587528/55.
 DR
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;
SQ

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNLTFRRTQTCOLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqrlrlllwknltfrtqtcollleavawplfiflilsvrlyppyeqhechfpnka 60

RESULT 9
B38111
ID B38111 standard; Protein; 2261 AA.
AC B38111;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, V771W.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX
OS Homo sapiens.
XX
PN WO200055318-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
PI Hayden MR, Wilson AR, Pimstone SN;
XX
XX WPI; 2000-587528/55.
DR
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer.
XX
XX Examples; Page -: 229pp; English.
PS
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNLTFRRTQTCOLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqrlrlllwknltfrtqtcollleavawplfiflilsvrlyppyeqhechfpnka 60

RESULT 10
B38112
ID B38112 standard; Protein; 2261 AA.
XX
AC B38112;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, T774P.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX
OS Homo sapiens.
XX
PN WO200055318-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX

PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI; 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX Examples; Page -: 229pp; English.
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX Sequence 2261 AA;
 SQ
 Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWNLTPRRRTQCOLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNKA 60
 Db 1 macwpqlrllllwnltfrrtqcolleavawplfllilslvrlsyppyeqhechfpnka 60
 RESULT 11
 B38113
 ID B38113 standard; Protein; 2261 AA.
 XX B38113;
 AC
 XX
 XX 29-JAN-2001 (first entry)
 DT
 XX Human ABC1 cholesterol transporter mutant, K776N.
 DE
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 XX ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 XX muten.
 XX Homo sapiens.
 OS
 XX WO200055318-A2.
 PN
 XX 21-SEP-2000.
 PD
 XX 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX (UVRB-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PA
 XX Hayden MR, Wilson AR, Pimstone SN;
 PI WPI; 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX Examples; Page -: 229pp; English.
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX

```
SQ Sequence 2261 AA;
Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLWKNLTFRRQTCQLLEAVWPLFIFLILSVRLSYPPYEQHECHFPNKA 60
    |||||||||||||||||||||||||||||||||||||||||||||||||||||||
DB 1 macwpqlrlwknltfrrrtcqllleavwplfiflilsvrlsyppyeqhechfpnka 60

RESULT 12
B38114
ID B38114 standard; Protein; 2261 AA.
XX
AC B38114;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, E1172D.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW mutin.
XX
OS Homo sapiens.
XX
PN WO2000055318-A2.
XX
PD 21-SEP-2000.
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
PI Hayden MR, Wilson AR, Pimstone SN;
XX
WPI; 2000-587528/55.
XX
New ABC1 polypeptide is useful for treating diseases associated with
ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
disease and cancer -
XX
Examples; Page -: 229pp; English.
XX
The invention relates to the human ABC1 cholesterol transporter protein
(B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
a member of the ATP-binding cassette (ABC transporter) superfamily of
proteins, and plays a crucial role in cholesterol transport, particularly
intracellular cholesterol trafficking in monocytes and fibroblasts, being
involved in cholesterol efflux from the cell. The gene encoding ABC1 is
located on chromosome 9q31, and mutations in this gene are associated
with two genetic HDL (high density lipoprotein) deficiency disorders,
Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
are distinguishable in that TD is an autosomal recessive disorder, while
FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
cholesterol") in the blood correlate with a high risk of cardiovascular
disease, particularly coronary artery disease, but also cerebrovascular
disease, coronary restenosis, and peripheral vascular disease.
Conversely, a high level of HDL has protective effects against
```


XX WPI; 2000-587528/55.

XX New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer.

XX

XX Examples: Page -: 229pp; English.

PS

XX The invention relates to the human ABC1 cholesterol transporter protein

XX (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is

CC a member of the ATP-binding cassette (ABC transporter) superfamily of

CC proteins, and plays a crucial role in cholesterol transport, particularly

CC intracellular cholesterol trafficking in monocytes and fibroblasts, being

CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated

CC with two genetic HDL (high density lipoprotein) deficiency disorders,

CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases

CC are distinguishable in that TD is an autosomal recessive disorder, while

CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

CC cholesterol") in the blood correlate with a high risk of cardiovascular

CC disease, particularly coronary artery disease, but also cerebrovascular

CC disease, coronary restenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic

CC acids, and methods of gene therapy for the treatment or prevention of

CC cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also

CC encompasses compounds which mimic ABC1 activity, compounds which

CC stimulate ABC1 expression and methods of screening for such compounds.

CC It further relates to methods for determining whether a patient has an

CC increased risk for cardiovascular disease due to polymorphisms in the

CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat

CC or prevent cardiovascular disease, especially coronary artery disease,

CC cerebrovascular disease, coronary restenosis or peripheral vascular

CC disease. They may also be used in the treatment of diseases associated

CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick

CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid

CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic

CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The

CC present sequence represents a mutant human ABC1 cholesterol transporter

CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is

CC derived from the native human ABC1 shown on pages 152-157.

XX

XX Sequence 2261 AA;

SQ

Query Match 100.0%; Score 334; DB 21; Length 2261;

Best Local Similarity 100.0%; Pred. No. 2.7e-37;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNLTFRRQTCLLLEVAWPLFLLISVRLSYPPYQHECHFPNKA 60

|||||

Db 1 macwpqlrlllwknltfrrqtclllleavawplfllilsvrlsyppyechechfpnka 60

RESULT 14

ID B38116

XX B38116 standard; Protein; 2261 AA.

AC

XX B38116;

XX

XX 29-JAN-2001 (first entry)

XX Human ABC1 cholesterol transporter mutant, S1731C.

XX

XX Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

KW cardiovascular disease; coronary artery disease; coronary restenosis;

KW cerebrovascular disease; peripheral vascular disease;

KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

KW mutin.

XX

OS Homo sapiens.

XX

PN WO200055318-A2.

XX

PD 21-SEP-2000.

XX

PF 15-MAR-2000; 2000WO-IB00532.

XX

PR 15-MAR-1999; 99US-0124702.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-0139600.

PR 01-SEP-1999; 99US-0151977.

XX

PA (UWBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX

PI Hayden MR, Wilson AR, Pimstone SN;

XX

DR WPI; 2000-587528/55.

XX

XX New ABC1 polypeptide is useful for treating diseases associated with

PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's

PT disease and cancer.

XX

XX Examples: Page -: 229pp; English.

PS

XX The invention relates to the human ABC1 cholesterol transporter protein

XX (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is

CC a member of the ATP-binding cassette (ABC transporter) superfamily of

CC proteins, and plays a crucial role in cholesterol transport, particularly

CC intracellular cholesterol trafficking in monocytes and fibroblasts, being

CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is

CC located on chromosome 9q31, and mutations in this gene are associated

CC with two genetic HDL (high density lipoprotein) deficiency disorders,

CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases

CC are distinguishable in that TD is an autosomal recessive disorder, while

CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good

CC cholesterol") in the blood correlate with a high risk of cardiovascular

CC disease, particularly coronary artery disease, but also cerebrovascular

CC disease, coronary restenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic

CC acids, and methods of gene therapy for the treatment or prevention of

CC cardiovascular disease comprising the administration of an expression

CC vector encoding ABC1 or an active fragment thereof. The invention also

CC encompasses compounds which mimic ABC1 activity, compounds which

CC stimulate ABC1 expression and methods of screening for such compounds.

CC It further relates to methods for determining whether a patient has an

CC increased risk for cardiovascular disease due to polymorphisms in the

CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat

CC or prevent cardiovascular disease, especially coronary artery disease,

CC cerebrovascular disease, coronary restenosis or peripheral vascular

CC disease. They may also be used in the treatment of diseases associated

CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick

CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid

CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic

CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The

CC present sequence represents a mutant human ABC1 cholesterol transporter

CC associated with an altered cholesterol level and therefore an altered

CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is

CC derived from the native human ABC1 shown on pages 152-157.

XX

XX Sequence 2261 AA;

SQ

Query Match 100.0%; Score 334; DB 21; Length 2261;

Best Local Similarity 100.0%; Pred. No. 2.7e-37;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNLTFRRQTCLLLEVAWPLFLLISVRLSYPPYQHECHFPNKA 60

|||||

Db 1 macwpqlrlllwknltfrrqtclllleavawplfllilsvrlsyppyechechfpnka 60

RESULT 14

ID B38116

XX B38116 standard; Protein; 2261 AA.

AC

XX B38116;

XX

XX 29-JAN-2001 (first entry)

XX Human ABC1 cholesterol transporter mutant, S1731C.

XX

XX Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLLNKNTFRRTQTCQLLELVAMPFLFLLISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqlrlllnkntfrrrtqcqllelvampflfllisvrlsyppyeqhechfpnka 60

RESULT 15
B38117
ID B38117 standard; Protein: 2261 AA.
AC B38117;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, I883M.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary stenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX
OS Homo sapiens.
XX
XX
FN WO200055318-A2.
XX
XX
PD 21-SEP-2000.
XX
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
XX
PI Hayden MR, Wilson AR, Pimstone SN;
XX
XX
DR WPI; 2000-587528/55.
XX
XX
PT New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX disease and cancer -
XX
PS Examples; Page -: 229pp; English.
XX

The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary stenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and

CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary stenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.

XX SQ Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLLNKNTFRRTQTCQLLELVAMPFLFLLISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqlrlllnkntfrrrtqcqllelvampflfllisvrlsyppyeqhechfpnka 60

Search completed: May 31, 2001, 13:03:56
Job time: 2907 sec